[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fxTC5o2JVcFYfuASakn9y7byralGAElX5RxdqYf_EF0k":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":83,"rows":90},"Kyowa Kirin Co., Ltd.",[4],157,false,13,51,25368,17,4,[14,16,19,22,25,27,29,31],{"name":15,"count":11},"Parkinson's Disease",{"name":17,"count":18},"Hyperphosphatemia",7,{"name":20,"count":21},"Secondary Hyperparathyroidism",6,{"name":23,"count":24},"X-linked Hypophosphatemia",5,{"name":26,"count":12},"Cancer",{"name":28,"count":12},"Type 2 Diabetes",{"name":30,"count":12},"Aplastic Anemia",{"name":32,"count":33},"Pain",3,[35,40,45,48,53,58,63,68,73,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05411016","A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus","2024-12-10","KK4277",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06116890","Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration","2026-08-31","KHK4951",{"nctId":46,"briefTitle":47,"date":43,"intervention":44},"NCT06116916","Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06812104","Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia","2026-12-31","KK2845_1",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06823947","Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension","2027-12","KK3910",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT06525636","A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia","2028-02-11","KK8123",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04533581","Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)","2028-05-31","ME-401",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT07132567","Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance","2028-09","Poteligeo 20mg",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06266299","A Study of KK2269 in Adult Participants With Solid Tumors","2029-03","KK2269",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06926491","Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）","2029-05-31","KK8398",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,115,159,181,213,234,256,283,301,319,337,355,373,399,420,447,465,488,601,630,657,675,765,847,925,1002,1052,1103,1154,1201,1241,1288,1328,1365,1397,1429,1459,1491,1519,1541,1565,1588,1606,1629,1647,1665,1688,1706,1731,1749,1775,1800,1818,1845,1863,1937,2002,2040,2079,2113,2148,2183,2205,2223,2246,2269,2294,2312,2330,2348,2371,2394,2412,2430,2448,2472,2497,2515,2540,2558,2599,2633,2651,2669,2687,2705,2723,2741,2764,2786,2810,2838,2856,2874,2892,2910,2933,2951,2979,2997,3015,3033,3060,3078,3096,3114,3132,3150,3168,3190,3208,3231,3256,3281,3299,3317,3338,3359,3380],{"intervention":82,"totalTrials":92,"cells":93},1,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":111,"NA":113},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":92,"soonestReadout":81},[103],{"nctId":79,"briefTitle":80,"status":104,"phases":105,"primaryCompletion":81,"completion":106,"start":107,"enrollment":21,"conditions":108,"interventions":110},"RECRUITING",[87],"2031-05-31","2024-12-01",[109],"Achondroplasia",[82],{"trials":112,"activeCount":96},[],{"trials":114,"activeCount":96},[],{"intervention":44,"totalTrials":33,"cells":116},{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":133,"PHASE3":153,"PHASE4":155,"NA":157},{"trials":118,"activeCount":96},[],{"trials":120,"activeCount":96},[121],{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":132},"NCT04594681","A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration","TERMINATED",[85],"2022-08-26","2020-09-16",116,[130,131],"Healthy Volunteers","Wet Age-related Macular Degeneration",[44],{"trials":134,"activeCount":152,"soonestReadout":43},[135,145],{"nctId":41,"briefTitle":42,"status":136,"phases":137,"primaryCompletion":43,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"ACTIVE_NOT_RECRUITING",[86],"2026-09-30","2024-01-31",180,[142],"Neovascular Age-Related Macular Degeneration (nAMD)",[44,144],"Aflibercept",{"nctId":46,"briefTitle":47,"status":136,"phases":146,"primaryCompletion":43,"completion":138,"start":147,"enrollment":148,"conditions":149,"interventions":151},[86],"2024-01-09",150,[150],"Diabetic Macular Edema (DME)",[44,144],2,{"trials":154,"activeCount":96},[],{"trials":156,"activeCount":96},[],{"trials":158,"activeCount":96},[],{"intervention":144,"totalTrials":152,"cells":160},{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":175,"PHASE4":177,"NA":179},{"trials":162,"activeCount":96},[],{"trials":164,"activeCount":96},[],{"trials":166,"activeCount":152,"soonestReadout":43},[167,171],{"nctId":41,"briefTitle":42,"status":136,"phases":168,"primaryCompletion":43,"completion":138,"start":139,"enrollment":140,"conditions":169,"interventions":170},[86],[142],[44,144],{"nctId":46,"briefTitle":47,"status":136,"phases":172,"primaryCompletion":43,"completion":138,"start":147,"enrollment":148,"conditions":173,"interventions":174},[86],[150],[44,144],{"trials":176,"activeCount":96},[],{"trials":178,"activeCount":96},[],{"trials":180,"activeCount":96},[],{"intervention":67,"totalTrials":152,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":198,"PHASE3":207,"PHASE4":209,"NA":211},{"trials":184,"activeCount":96},[],{"trials":186,"activeCount":96},[187],{"nctId":188,"briefTitle":189,"status":190,"phases":191,"primaryCompletion":192,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT03985189","Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma","COMPLETED",[85],"2025-01-15","2019-04-29",14,[196],"Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma",[67],{"trials":199,"activeCount":92,"soonestReadout":66},[200],{"nctId":64,"briefTitle":65,"status":136,"phases":201,"primaryCompletion":66,"completion":66,"start":202,"enrollment":203,"conditions":204,"interventions":206},[86],"2020-09-17",61,[205],"Indolent B-cell Non-Hodgkin's Lymphoma",[67],{"trials":208,"activeCount":96},[],{"trials":210,"activeCount":96},[],{"trials":212,"activeCount":96},[],{"intervention":62,"totalTrials":92,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":216,"activeCount":96},[],{"trials":218,"activeCount":96},[],{"trials":220,"activeCount":92,"soonestReadout":61},[221],{"nctId":59,"briefTitle":60,"status":104,"phases":222,"primaryCompletion":61,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":227},[85,86],"2028-05-10","2024-10-09",24,[23],[62],{"trials":229,"activeCount":96},[],{"trials":231,"activeCount":96},[],{"trials":233,"activeCount":96},[],{"intervention":39,"totalTrials":92,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":248,"PHASE3":250,"PHASE4":252,"NA":254},{"trials":237,"activeCount":96},[],{"trials":239,"activeCount":92,"soonestReadout":38},[240],{"nctId":36,"briefTitle":37,"status":136,"phases":241,"primaryCompletion":38,"completion":242,"start":243,"enrollment":6,"conditions":244,"interventions":247},[85],"2025-12","2022-08-03",[130,245,246],"Systemic Lupus Erythematosus (SLE)","Cutaneous Lupus Erythematosus (CLE)",[39],{"trials":249,"activeCount":96},[],{"trials":251,"activeCount":96},[],{"trials":253,"activeCount":96},[],{"trials":255,"activeCount":96},[],{"intervention":52,"totalTrials":92,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":281},{"trials":259,"activeCount":96},[],{"trials":261,"activeCount":92,"soonestReadout":51},[262],{"nctId":49,"briefTitle":50,"status":104,"phases":263,"primaryCompletion":51,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":269},[85],"2028-04-30","2024-10-10",72,[268],"Relapsed or Refractory Acute Myeloid Leukemia",[52,270,271,272,273,274],"KK2845_2","KK2845_3","KK2845_4","KK2845_5","KK2845_6",{"trials":276,"activeCount":96},[],{"trials":278,"activeCount":96},[],{"trials":280,"activeCount":96},[],{"trials":282,"activeCount":96},[],{"intervention":270,"totalTrials":92,"cells":284},{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":299},{"trials":286,"activeCount":96},[],{"trials":288,"activeCount":92,"soonestReadout":51},[289],{"nctId":49,"briefTitle":50,"status":104,"phases":290,"primaryCompletion":51,"completion":264,"start":265,"enrollment":266,"conditions":291,"interventions":292},[85],[268],[52,270,271,272,273,274],{"trials":294,"activeCount":96},[],{"trials":296,"activeCount":96},[],{"trials":298,"activeCount":96},[],{"trials":300,"activeCount":96},[],{"intervention":271,"totalTrials":92,"cells":302},{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":311,"PHASE3":313,"PHASE4":315,"NA":317},{"trials":304,"activeCount":96},[],{"trials":306,"activeCount":92,"soonestReadout":51},[307],{"nctId":49,"briefTitle":50,"status":104,"phases":308,"primaryCompletion":51,"completion":264,"start":265,"enrollment":266,"conditions":309,"interventions":310},[85],[268],[52,270,271,272,273,274],{"trials":312,"activeCount":96},[],{"trials":314,"activeCount":96},[],{"trials":316,"activeCount":96},[],{"trials":318,"activeCount":96},[],{"intervention":272,"totalTrials":92,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":335},{"trials":322,"activeCount":96},[],{"trials":324,"activeCount":92,"soonestReadout":51},[325],{"nctId":49,"briefTitle":50,"status":104,"phases":326,"primaryCompletion":51,"completion":264,"start":265,"enrollment":266,"conditions":327,"interventions":328},[85],[268],[52,270,271,272,273,274],{"trials":330,"activeCount":96},[],{"trials":332,"activeCount":96},[],{"trials":334,"activeCount":96},[],{"trials":336,"activeCount":96},[],{"intervention":273,"totalTrials":92,"cells":338},{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":353},{"trials":340,"activeCount":96},[],{"trials":342,"activeCount":92,"soonestReadout":51},[343],{"nctId":49,"briefTitle":50,"status":104,"phases":344,"primaryCompletion":51,"completion":264,"start":265,"enrollment":266,"conditions":345,"interventions":346},[85],[268],[52,270,271,272,273,274],{"trials":348,"activeCount":96},[],{"trials":350,"activeCount":96},[],{"trials":352,"activeCount":96},[],{"trials":354,"activeCount":96},[],{"intervention":274,"totalTrials":92,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":365,"PHASE3":367,"PHASE4":369,"NA":371},{"trials":358,"activeCount":96},[],{"trials":360,"activeCount":92,"soonestReadout":51},[361],{"nctId":49,"briefTitle":50,"status":104,"phases":362,"primaryCompletion":51,"completion":264,"start":265,"enrollment":266,"conditions":363,"interventions":364},[85],[268],[52,270,271,272,273,274],{"trials":366,"activeCount":96},[],{"trials":368,"activeCount":96},[],{"trials":370,"activeCount":96},[],{"trials":372,"activeCount":96},[],{"intervention":374,"totalTrials":92,"cells":375},"KK2260",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":397},{"trials":377,"activeCount":96},[],{"trials":379,"activeCount":92,"soonestReadout":384},[380],{"nctId":381,"briefTitle":382,"status":104,"phases":383,"primaryCompletion":384,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":390},"NCT06248411","A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors",[85],"2029-10-31","2030-04-30","2023-11-01",189,[389],"Advanced or Metastatic Solid Tumors",[374,374],{"trials":392,"activeCount":96},[],{"trials":394,"activeCount":96},[],{"trials":396,"activeCount":96},[],{"trials":398,"activeCount":96},[],{"intervention":57,"totalTrials":92,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":412,"PHASE3":414,"PHASE4":416,"NA":418},{"trials":402,"activeCount":96},[],{"trials":404,"activeCount":92,"soonestReadout":56},[405],{"nctId":54,"briefTitle":55,"status":104,"phases":406,"primaryCompletion":56,"completion":56,"start":407,"enrollment":408,"conditions":409,"interventions":411},[85],"2025-04-03",160,[410],"Healthy Volunteers Essential Hypertension",[57],{"trials":413,"activeCount":96},[],{"trials":415,"activeCount":96},[],{"trials":417,"activeCount":96},[],{"trials":419,"activeCount":96},[],{"intervention":77,"totalTrials":92,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":445},{"trials":423,"activeCount":96},[],{"trials":425,"activeCount":92,"soonestReadout":76},[426],{"nctId":74,"briefTitle":75,"status":104,"phases":427,"primaryCompletion":76,"completion":76,"start":428,"enrollment":429,"conditions":430,"interventions":437},[85],"2024-01-18",101,[431,432,433,434,435,436],"Advanced Solid Tumor","Metastatic Solid Tumor","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma","Non Small Cell Lung Cancer",[77,438],"Docetaxel",{"trials":440,"activeCount":96},[],{"trials":442,"activeCount":96},[],{"trials":444,"activeCount":96},[],{"trials":446,"activeCount":96},[],{"intervention":438,"totalTrials":92,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":457,"PHASE3":459,"PHASE4":461,"NA":463},{"trials":450,"activeCount":96},[],{"trials":452,"activeCount":92,"soonestReadout":76},[453],{"nctId":74,"briefTitle":75,"status":104,"phases":454,"primaryCompletion":76,"completion":76,"start":428,"enrollment":429,"conditions":455,"interventions":456},[85],[431,432,433,434,435,436],[77,438],{"trials":458,"activeCount":96},[],{"trials":460,"activeCount":96},[],{"trials":462,"activeCount":96},[],{"trials":464,"activeCount":96},[],{"intervention":72,"totalTrials":92,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":468,"activeCount":96},[],{"trials":470,"activeCount":96},[],{"trials":472,"activeCount":96},[],{"trials":474,"activeCount":96},[],{"trials":476,"activeCount":96},[],{"trials":478,"activeCount":92,"soonestReadout":71},[479],{"nctId":69,"briefTitle":70,"status":104,"phases":480,"primaryCompletion":71,"completion":481,"start":482,"enrollment":483,"conditions":484,"interventions":487},[],"2028-11","2025-05-02",15,[485,486],"Mycosis Fungoides","Sezary Syndrome",[72],{"intervention":489,"totalTrials":490,"cells":491},"KRN23",10,{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":515,"PHASE3":546,"PHASE4":567,"NA":599},{"trials":493,"activeCount":96},[],{"trials":495,"activeCount":96},[496,506],{"nctId":497,"briefTitle":498,"status":190,"phases":499,"primaryCompletion":500,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":505},"NCT00830674","A Study of KRN23 in X-linked Hypophosphatemia",[85],"2011-12","2013-05","2008-12",42,[23],[489],{"nctId":507,"briefTitle":508,"status":190,"phases":509,"primaryCompletion":510,"completion":510,"start":511,"enrollment":483,"conditions":512,"interventions":514},"NCT02181764","A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets\u002FOsteomalacia",[85],"2015-06","2014-07",[513],"X-linked Hypophosphatemic Rickets\u002FOsteomalacia",[489],{"trials":516,"activeCount":96},[517,527,536],{"nctId":518,"briefTitle":519,"status":190,"phases":520,"primaryCompletion":521,"completion":522,"start":523,"enrollment":194,"conditions":524,"interventions":526},"NCT02722798","A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome",[86],"2017-07","2020-10","2016-04",[525],"Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome",[489],{"nctId":528,"briefTitle":529,"status":190,"phases":530,"primaryCompletion":501,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":535},"NCT01340482","A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia",[85,86],"2013-10","2011-04",29,[23],[489],{"nctId":537,"briefTitle":538,"status":190,"phases":539,"primaryCompletion":540,"completion":541,"start":542,"enrollment":543,"conditions":544,"interventions":545},"NCT01571596","An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia",[85,86],"2013-09","2014-06","2012-02",23,[23],[489],{"trials":547,"activeCount":96},[548,557],{"nctId":549,"briefTitle":550,"status":190,"phases":551,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":556},"NCT03233126","A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets\u002FOsteomalacia",[87],"2020-02-17","2017-07-06",16,[513],[489],{"nctId":558,"briefTitle":559,"status":190,"phases":560,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":566},"NCT04308096","A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets\u002FOsteomalacia",[87],"2020-12-04","2018-01-09",27,[565],"XLH",[489],{"trials":568,"activeCount":96},[569,580,590],{"nctId":570,"briefTitle":571,"status":190,"phases":572,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":579},"NCT05357573","Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO",[88],"2023-11-22","2023-12-22","2022-09-07",9,[578],"Tumor-Induced Osteomalacia (TIO)",[489],{"nctId":581,"briefTitle":582,"status":190,"phases":583,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":589},"NCT04842032","Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH",[88],"2023-12-18","2021-11-01",28,[588],"X-linked Hypophosphatemia (XLH)",[489],{"nctId":591,"briefTitle":592,"status":190,"phases":593,"primaryCompletion":594,"completion":594,"start":595,"enrollment":596,"conditions":597,"interventions":598},"NCT04842019","Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH",[88],"2023-08-17","2021-09-28",18,[588],[489],{"trials":600,"activeCount":96},[],{"intervention":602,"totalTrials":92,"cells":603},"Brodalumab 210mg SC",{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":610,"PHASE4":612,"NA":628},{"trials":605,"activeCount":96},[],{"trials":607,"activeCount":96},[],{"trials":609,"activeCount":96},[],{"trials":611,"activeCount":96},[],{"trials":613,"activeCount":96},[614],{"nctId":615,"briefTitle":616,"status":190,"phases":617,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":627},"NCT04183881","A Phase 4 Clinical Study of Brodalumab",[88],"2017-01-10","2017-07-24","2016-07-04",138,[623,624,625,626],"Psoriasis Vulgaris","Psoriatic Arthritis","Pustular; Psoriasis, Palmaris Et Plantaris","Psoriatic Erythroderma",[602],{"trials":629,"activeCount":96},[],{"intervention":631,"totalTrials":92,"cells":632},"KHK4827-Active",{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":641,"NA":655},{"trials":634,"activeCount":96},[],{"trials":636,"activeCount":96},[],{"trials":638,"activeCount":96},[],{"trials":640,"activeCount":96},[],{"trials":642,"activeCount":96},[643],{"nctId":644,"briefTitle":645,"status":646,"phases":647,"primaryCompletion":648,"completion":649,"start":650,"enrollment":96,"conditions":651,"interventions":653},"NCT04614298","A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis","WITHDRAWN",[88],"2022-02","2022-11","2021-01",[652],"Moderate to Severe Plaque Psoriasis",[631,654],"KHK4827-Placebo",{"trials":656,"activeCount":96},[],{"intervention":654,"totalTrials":92,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":667,"NA":673},{"trials":660,"activeCount":96},[],{"trials":662,"activeCount":96},[],{"trials":664,"activeCount":96},[],{"trials":666,"activeCount":96},[],{"trials":668,"activeCount":96},[669],{"nctId":644,"briefTitle":645,"status":646,"phases":670,"primaryCompletion":648,"completion":649,"start":650,"enrollment":96,"conditions":671,"interventions":672},[88],[652],[631,654],{"trials":674,"activeCount":96},[],{"intervention":676,"totalTrials":677,"cells":678},"Istradefylline",8,{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":703,"PHASE3":732,"PHASE4":761,"NA":763},{"trials":680,"activeCount":96},[],{"trials":682,"activeCount":96},[683,693],{"nctId":684,"briefTitle":685,"status":190,"phases":686,"primaryCompletion":687,"completion":687,"start":688,"enrollment":503,"conditions":689,"interventions":691},"NCT02609477","A Study to Evaluate Abuse Potential of Istradefylline",[85],"2016-07","2016-01",[690],"Drug Abuse",[676,692],"Phentermine 45 mg",{"nctId":694,"briefTitle":695,"status":190,"phases":696,"primaryCompletion":697,"completion":697,"start":698,"enrollment":699,"conditions":700,"interventions":702},"NCT02256033","Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline",[85],"2014-12","2014-08",20,[701],"Hepatic Impairment",[676],{"trials":704,"activeCount":96},[705,714,723],{"nctId":706,"briefTitle":707,"status":190,"phases":708,"primaryCompletion":709,"completion":709,"start":710,"enrollment":711,"conditions":712,"interventions":713},"NCT00455507","A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa",[86],"2008-08","2007-03",363,[15],[676,676],{"nctId":715,"briefTitle":716,"status":190,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":722},"NCT00199355","A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa",[86],"2006-03","2005-04",75,[15],[676],{"nctId":724,"briefTitle":725,"status":190,"phases":726,"primaryCompletion":727,"completion":727,"start":728,"enrollment":729,"conditions":730,"interventions":731},"NCT00250393","A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease",[86],"2006-10","2005-11",64,[15],[676],{"trials":733,"activeCount":96},[734,742,752],{"nctId":735,"briefTitle":725,"status":190,"phases":736,"primaryCompletion":737,"completion":728,"start":738,"enrollment":739,"conditions":740,"interventions":741},"NCT00199394",[87],"2005-10","2004-11",405,[15],[676],{"nctId":743,"briefTitle":744,"status":190,"phases":745,"primaryCompletion":746,"completion":747,"start":748,"enrollment":749,"conditions":750,"interventions":751},"NCT00957203","Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients",[87],"2011-09","2012-03","2009-10",308,[15],[676],{"nctId":753,"briefTitle":754,"status":190,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":760},"NCT00955526","Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa",[87],"2011-02","2009-07",373,[15],[676,676],{"trials":762,"activeCount":96},[],{"trials":764,"activeCount":96},[],{"intervention":766,"totalTrials":18,"cells":767},"KHK4827",{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":792,"PHASE3":802,"PHASE4":843,"NA":845},{"trials":769,"activeCount":96},[],{"trials":771,"activeCount":96},[772,782],{"nctId":773,"briefTitle":774,"status":190,"phases":775,"primaryCompletion":776,"completion":777,"start":778,"enrollment":677,"conditions":779,"interventions":781},"NCT04368403","A Study of KHK4827 in Patients With Systemic Sclerosis",[85],"2019-01-31","2025-03-31","2017-10-06",[780],"Systemic Sclerosis",[766],{"nctId":783,"briefTitle":784,"status":190,"phases":785,"primaryCompletion":786,"completion":786,"start":787,"enrollment":788,"conditions":789,"interventions":791},"NCT01488201","A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis",[85],"2012-09","2011-11",48,[790],"Psoriasis",[766],{"trials":793,"activeCount":96},[794],{"nctId":795,"briefTitle":796,"status":190,"phases":797,"primaryCompletion":540,"completion":540,"start":798,"enrollment":799,"conditions":800,"interventions":801},"NCT01748539","A Phase 2 Clinical Study of KHK4827",[86],"2012-12",140,[652],[766],{"trials":803,"activeCount":96},[804,812,821,832],{"nctId":805,"briefTitle":806,"status":190,"phases":807,"primaryCompletion":697,"completion":697,"start":808,"enrollment":809,"conditions":810,"interventions":811},"NCT01782937","An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis",[87],"2013-02",30,[790],[766],{"nctId":813,"briefTitle":814,"status":190,"phases":815,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":819,"interventions":820},"NCT01782924","A Phase 3 Clinical Study of KHK4827",[87],"2015-02","2013-03",145,[790],[766],{"nctId":822,"briefTitle":823,"status":190,"phases":824,"primaryCompletion":825,"completion":826,"start":827,"enrollment":828,"conditions":829,"interventions":831},"NCT04061252","A Study of KHK4827 in Subjects With Palmoplantar Pustulosis",[87],"2021-08-11","2022-08-05","2019-08-10",126,[830],"Palmoplantar Pustulosis",[766],{"nctId":833,"briefTitle":834,"status":190,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":842},"NCT03957681","A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis",[87],"2020-10-16","2025-04-11","2019-05-23",100,[841],"Moderate to Severe Systemic Sclerosis",[766],{"trials":844,"activeCount":96},[],{"trials":846,"activeCount":96},[],{"intervention":848,"totalTrials":18,"cells":849},"KHK7791",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":884,"PHASE4":921,"NA":923},{"trials":851,"activeCount":96},[],{"trials":853,"activeCount":96},[],{"trials":855,"activeCount":96},[856,865,875],{"nctId":857,"briefTitle":858,"status":190,"phases":859,"primaryCompletion":860,"completion":860,"start":861,"enrollment":862,"conditions":863,"interventions":864},"NCT03831607","A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD",[86],"2019-11-26","2018-12-27",67,[17],[848],{"nctId":866,"briefTitle":867,"status":190,"phases":868,"primaryCompletion":869,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":874},"NCT03864458","Dose-finding Study of KHK7791 in Hyperphosphatemia Patients",[86],"2019-12-10","2019-12-31","2019-04-15",207,[17],[848],{"nctId":876,"briefTitle":877,"status":190,"phases":878,"primaryCompletion":879,"completion":879,"start":193,"enrollment":880,"conditions":881,"interventions":882},"NCT03864445","Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients",[86],"2019-12-03",47,[17],[848,883],"Placebp",{"trials":885,"activeCount":96},[886,895,903,912],{"nctId":887,"briefTitle":888,"status":190,"phases":889,"primaryCompletion":890,"completion":890,"start":891,"enrollment":892,"conditions":893,"interventions":894},"NCT04766398","Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis",[87],"2021-09-27","2021-03-15",169,[17],[848],{"nctId":896,"briefTitle":897,"status":190,"phases":898,"primaryCompletion":899,"completion":899,"start":891,"enrollment":900,"conditions":901,"interventions":902},"NCT04771780","Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis",[87],"2022-06-27",213,[17],[848],{"nctId":904,"briefTitle":905,"status":190,"phases":906,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":911},"NCT04766385","Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis",[87],"2021-12-01","2021-03-03",54,[17],[848],{"nctId":913,"briefTitle":914,"status":190,"phases":915,"primaryCompletion":916,"completion":916,"start":917,"enrollment":918,"conditions":919,"interventions":920},"NCT04767581","Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis",[87],"2021-08-10","2021-03-08",165,[17],[848],{"trials":922,"activeCount":96},[],{"trials":924,"activeCount":96},[],{"intervention":926,"totalTrials":18,"cells":927},"KHK7580",{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":939,"PHASE3":950,"PHASE4":998,"NA":1000},{"trials":929,"activeCount":96},[],{"trials":931,"activeCount":96},[932],{"nctId":933,"briefTitle":934,"status":190,"phases":935,"primaryCompletion":697,"completion":697,"start":936,"enrollment":8,"conditions":937,"interventions":938},"NCT02143271","Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis",[85],"2014-05",[20],[926],{"trials":940,"activeCount":96},[941],{"nctId":942,"briefTitle":943,"status":190,"phases":944,"primaryCompletion":945,"completion":945,"start":946,"enrollment":699,"conditions":947,"interventions":949},"NCT01935856","Phase 1\u002F2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis",[85,86],"2014-03","2013-08",[948],"Hyperparathyroidism",[926],{"trials":951,"activeCount":96},[952,962,971,980,989],{"nctId":953,"briefTitle":954,"status":190,"phases":955,"primaryCompletion":956,"completion":956,"start":957,"enrollment":958,"conditions":959,"interventions":960},"NCT03822507","Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia",[87],"2021-09-23","2019-04-09",404,[20],[926,961],"Cinacalcet Hydrochloride",{"nctId":963,"briefTitle":964,"status":190,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":970},"NCT02549417","Phase 3 Study of KHK7580",[87],"2016-12-22","2015-09-29",39,[20],[926],{"nctId":972,"briefTitle":973,"status":190,"phases":974,"primaryCompletion":957,"completion":957,"start":975,"enrollment":596,"conditions":976,"interventions":979},"NCT03280264","Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism",[87],"2017-08-30",[977,978],"Parathyroid Carcinoma","Primary Hyperparathyroidism",[926],{"nctId":981,"briefTitle":964,"status":190,"phases":982,"primaryCompletion":983,"completion":983,"start":984,"enrollment":985,"conditions":986,"interventions":987},"NCT02549391",[86,87],"2016-11","2015-09",634,[20],[926,988],"KRN1493",{"nctId":990,"briefTitle":964,"status":190,"phases":991,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":997},"NCT02549404",[87],"2016-12-06","2016-12-28","2015-09-28",137,[20],[926],{"trials":999,"activeCount":96},[],{"trials":1001,"activeCount":96},[],{"intervention":1003,"totalTrials":12,"cells":1004},"KW-2246",{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1009,"PHASE3":1020,"PHASE4":1048,"NA":1050},{"trials":1006,"activeCount":96},[],{"trials":1008,"activeCount":96},[],{"trials":1010,"activeCount":96},[1011],{"nctId":1012,"briefTitle":1013,"status":190,"phases":1014,"primaryCompletion":1015,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1019},"NCT00355628","Clinical Study of KW-2246 in Patients With Cancer Pain",[86],"2007-07","2006-07",40,[32,26],[1003],{"trials":1021,"activeCount":96},[1022,1032,1039],{"nctId":1023,"briefTitle":1024,"status":190,"phases":1025,"primaryCompletion":757,"completion":1026,"start":1027,"enrollment":1028,"conditions":1029,"interventions":1031},"NCT00683995","A Phase III Clinical Study of KW-2246",[87],"2011-10","2008-03",43,[1030],"Pain, Cancer",[1003],{"nctId":1033,"briefTitle":1034,"status":190,"phases":1035,"primaryCompletion":1036,"completion":1036,"start":1027,"enrollment":9,"conditions":1037,"interventions":1038},"NCT00684632","A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients",[87],"2009-04",[1030],[1003],{"nctId":1040,"briefTitle":1041,"status":190,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":503,"conditions":1045,"interventions":1047},"NCT01326689","A Comparative Study of KW-2246",[87],"2012-06","2011-03",[1046],"Cancer Related Pain (Breakthrough Pain)",[1003],{"trials":1049,"activeCount":96},[],{"trials":1051,"activeCount":96},[],{"intervention":1053,"totalTrials":12,"cells":1054},"granisetron",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1085,"PHASE3":1087,"PHASE4":1099,"NA":1101},{"trials":1056,"activeCount":96},[],{"trials":1058,"activeCount":96},[1059,1068,1077],{"nctId":1060,"briefTitle":1061,"status":190,"phases":1062,"primaryCompletion":1063,"completion":1063,"start":1036,"enrollment":1064,"conditions":1065,"interventions":1067},"NCT00868764","An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron",[85],"2009-09",60,[1066],"Pharmacokinetics",[1053],{"nctId":1069,"briefTitle":1070,"status":190,"phases":1071,"primaryCompletion":1072,"completion":1072,"start":1036,"enrollment":1073,"conditions":1074,"interventions":1076},"NCT00873197","PK, Tolerability and Safety of the Co-administration of Sancuso® (Transdermal Granisetron) and IV Granisetron",[85],"2009-05",12,[1075],"Healthy",[1053],{"nctId":1078,"briefTitle":1079,"status":190,"phases":1080,"primaryCompletion":1081,"completion":1063,"start":1072,"enrollment":1082,"conditions":1083,"interventions":1084},"NCT00890565","Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)",[85],"2009-08",240,[1075],[1053],{"trials":1086,"activeCount":96},[],{"trials":1088,"activeCount":96},[1089],{"nctId":1090,"briefTitle":1091,"status":190,"phases":1092,"completion":727,"start":1093,"enrollment":1094,"conditions":1095,"interventions":1097},"NCT00273468","To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)",[87],"2006-01",630,[1096],"Chemotherapy-induced Nausea and Vomiting",[1098],"Granisetron",{"trials":1100,"activeCount":96},[],{"trials":1102,"activeCount":96},[],{"intervention":1104,"totalTrials":12,"cells":1105},"Romiplostim",{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1121,"PHASE4":1150,"NA":1152},{"trials":1107,"activeCount":96},[],{"trials":1109,"activeCount":96},[],{"trials":1111,"activeCount":96},[1112],{"nctId":1113,"briefTitle":1114,"status":190,"phases":1115,"primaryCompletion":1116,"completion":1116,"start":1117,"enrollment":1073,"conditions":1118,"interventions":1120},"NCT00305435","Safety Study of AMG 531 in Japanese Subjects With ITP",[86],"2006-11","2006-02",[1119],"Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",[1104],{"trials":1122,"activeCount":96},[1123,1132,1140],{"nctId":1124,"briefTitle":1125,"status":190,"phases":1126,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":11,"conditions":1130,"interventions":1131},"NCT03957694","Study of AMG531(Romiplostim) in Patients With Aplastic Anemia",[86,87],"2020-11-05","2021-05-26","2019-04-25",[30],[1104],{"nctId":1133,"briefTitle":1134,"status":190,"phases":1135,"primaryCompletion":1136,"completion":1137,"start":879,"enrollment":225,"conditions":1138,"interventions":1139},"NCT04095936","Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia",[86,87],"2021-10-07","2021-10-29",[30],[1104],{"nctId":1141,"briefTitle":1142,"status":190,"phases":1143,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1147,"conditions":1148,"interventions":1149},"NCT02773290","Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia",[86,87],"2017-11-14","2020-07-28","2016-05",46,[30],[1104],{"trials":1151,"activeCount":96},[],{"trials":1153,"activeCount":96},[],{"intervention":1155,"totalTrials":12,"cells":1156},"KW-3357",{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1169,"PHASE3":1171,"PHASE4":1197,"NA":1199},{"trials":1158,"activeCount":96},[],{"trials":1160,"activeCount":96},[1161],{"nctId":1162,"briefTitle":1163,"status":190,"phases":1164,"primaryCompletion":1165,"completion":532,"start":1036,"enrollment":554,"conditions":1166,"interventions":1168},"NCT00938288","A Study of KW-3357 in Congenital Antithrombin Deficiency",[85],"2010-12-22",[1167],"Congenital Antithrombin Deficiency",[1155],{"trials":1170,"activeCount":96},[],{"trials":1172,"activeCount":96},[1173,1181,1190],{"nctId":1174,"briefTitle":1175,"status":124,"phases":1176,"primaryCompletion":1177,"completion":1177,"start":542,"enrollment":24,"conditions":1178,"interventions":1180},"NCT01384409","A Phase 3 Clinical Study of KW-3357 in Patients With DIC",[87],"2012-10",[1179],"Disseminated Intravascular Coagulation (DIC)",[1155],{"nctId":1182,"briefTitle":1183,"status":190,"phases":1184,"primaryCompletion":501,"completion":501,"start":1185,"enrollment":1186,"conditions":1187,"interventions":1188},"NCT01384903","An Open-label Study of KW-3357",[87],"2011-06",221,[1179],[1155,1189],"Plasma-derived antithrombin",{"nctId":1191,"briefTitle":1192,"status":190,"phases":1193,"primaryCompletion":1194,"completion":1194,"start":500,"enrollment":483,"conditions":1195,"interventions":1196},"NCT01384396","A Clinical Study of KW-3357 in Patients With DIC",[87],"2013-04",[1179],[1155],{"trials":1198,"activeCount":96},[],{"trials":1200,"activeCount":96},[],{"intervention":1202,"totalTrials":33,"cells":1203},"OPC-262",{"EARLY_PHASE1":1204,"PHASE1":1206,"PHASE2":1208,"PHASE3":1210,"PHASE4":1237,"NA":1239},{"trials":1205,"activeCount":96},[],{"trials":1207,"activeCount":96},[],{"trials":1209,"activeCount":96},[],{"trials":1211,"activeCount":96},[1212,1220,1228],{"nctId":1213,"briefTitle":1214,"status":190,"phases":1215,"primaryCompletion":1185,"completion":1185,"start":1081,"enrollment":1216,"conditions":1217,"interventions":1219},"NCT01634282","Along-term Study of OPC-262 in Patients With Type 2 Diabetes",[87],222,[1218],"Diabetes, Type 2",[1202],{"nctId":1221,"briefTitle":1222,"status":190,"phases":1223,"primaryCompletion":1224,"completion":1224,"start":1225,"enrollment":839,"conditions":1226,"interventions":1227},"NCT01046318","A Study of OPC-262 in Patients With Type 2 Diabetes",[87],"2011-07","2009-11",[28],[1202],{"nctId":1229,"briefTitle":1230,"status":190,"phases":1231,"primaryCompletion":1232,"completion":1232,"start":1233,"enrollment":1234,"conditions":1235,"interventions":1236},"NCT01193179","A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes",[87],"2012-04","2010-07",450,[1218],[1202],{"trials":1238,"activeCount":96},[],{"trials":1240,"activeCount":96},[],{"intervention":1242,"totalTrials":33,"cells":1243},"Bardoxolone methyl",{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1269,"PHASE3":1271,"PHASE4":1284,"NA":1286},{"trials":1245,"activeCount":96},[],{"trials":1247,"activeCount":96},[1248,1259],{"nctId":1249,"briefTitle":1250,"status":190,"phases":1251,"primaryCompletion":1252,"completion":1253,"start":1254,"enrollment":1255,"conditions":1256,"interventions":1258},"NCT04018339","A Study of RTA 402 in Obese Adults",[85],"2020-05-28","2020-06-18","2019-08-20",22,[1257],"Obese Adult Male",[1242],{"nctId":1260,"briefTitle":1261,"status":190,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1268},"NCT04023903","A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy Adults",[85],"2019-06-14","2019-04-04",36,[1267],"Healthy Subject",[1242,1242],{"trials":1270,"activeCount":96},[],{"trials":1272,"activeCount":96},[1273],{"nctId":1274,"briefTitle":1275,"status":124,"phases":1276,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1283},"NCT03550443","A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study",[87],"2022-11-30","2023-07-31","2018-05-30",1323,[1282],"Diabetic Kidney Disease",[1242],{"trials":1285,"activeCount":96},[],{"trials":1287,"activeCount":96},[],{"intervention":1289,"totalTrials":33,"cells":1290},"KW-6500",{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1297,"PHASE4":1324,"NA":1326},{"trials":1292,"activeCount":96},[],{"trials":1294,"activeCount":96},[],{"trials":1296,"activeCount":96},[],{"trials":1298,"activeCount":96},[1299,1307,1315],{"nctId":1300,"briefTitle":1301,"status":190,"phases":1302,"primaryCompletion":1303,"completion":747,"start":1304,"enrollment":563,"conditions":1305,"interventions":1306},"NCT01063621","Extended Long-Term Safety Study of KW-6500",[87],"2011-08","2010-01",[15],[1289],{"nctId":1308,"briefTitle":1309,"status":190,"phases":1310,"primaryCompletion":1311,"completion":747,"start":757,"enrollment":1312,"conditions":1313,"interventions":1314},"NCT00955318","Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease",[87],"2010-12",58,[15],[1289],{"nctId":1316,"briefTitle":1317,"status":190,"phases":1318,"primaryCompletion":1319,"completion":1319,"start":1304,"enrollment":1320,"conditions":1321,"interventions":1322},"NCT01058291","Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500",[87],"2010-10",31,[15],[1289,1323],"KW-6500 Placebo",{"trials":1325,"activeCount":96},[],{"trials":1327,"activeCount":96},[],{"intervention":1329,"totalTrials":33,"cells":1330},"ARQ 197 and Erlotinib",{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1350,"PHASE3":1352,"PHASE4":1361,"NA":1363},{"trials":1332,"activeCount":96},[],{"trials":1334,"activeCount":96},[1335,1343],{"nctId":1336,"briefTitle":1337,"status":190,"phases":1338,"primaryCompletion":1339,"completion":1339,"start":1311,"enrollment":576,"conditions":1340,"interventions":1342},"NCT01251796","A Study of ARQ 197 in Combination With Erlotinib",[85],"2012-11",[1341],"Advanced\u002FRecurrent Non-small-cell Lung Cancer",[1329],{"nctId":1344,"briefTitle":1337,"status":190,"phases":1345,"primaryCompletion":746,"completion":746,"start":1346,"enrollment":554,"conditions":1347,"interventions":1349},"NCT01069757",[85],"2010-02",[1348],"Non-small-cell Lung Cancer",[1329],{"trials":1351,"activeCount":96},[],{"trials":1353,"activeCount":96},[1354],{"nctId":1355,"briefTitle":1356,"status":124,"phases":1357,"primaryCompletion":1358,"start":1224,"conditions":1359,"interventions":1360},"NCT01377376","A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib",[87],"2015-11",[1348],[1329],{"trials":1362,"activeCount":96},[],{"trials":1364,"activeCount":96},[],{"intervention":1366,"totalTrials":152,"cells":1367},"Istradefylline 40 mg",{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1379,"PHASE3":1381,"PHASE4":1393,"NA":1395},{"trials":1369,"activeCount":96},[],{"trials":1371,"activeCount":96},[1372],{"nctId":1373,"briefTitle":1374,"status":190,"phases":1375,"primaryCompletion":698,"completion":697,"start":541,"enrollment":699,"conditions":1376,"interventions":1377},"NCT02174250","The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.",[85],[15],[1366,1378],"Rifampin 300mg BID + istradefylline 40mg Day 8 only",{"trials":1380,"activeCount":96},[],{"trials":1382,"activeCount":96},[1383],{"nctId":1384,"briefTitle":1385,"status":190,"phases":1386,"primaryCompletion":1387,"completion":1387,"start":531,"enrollment":1388,"conditions":1389,"interventions":1391},"NCT01968031","A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease",[87],"2016-10",613,[1390],"Idiopathic Parkinson's Disease",[1366,1392],"Istradefylline 20 mg",{"trials":1394,"activeCount":96},[],{"trials":1396,"activeCount":96},[],{"intervention":1398,"totalTrials":152,"cells":1399},"ARQ197",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1411,"PHASE3":1413,"PHASE4":1425,"NA":1427},{"trials":1401,"activeCount":96},[],{"trials":1403,"activeCount":96},[1404],{"nctId":1405,"briefTitle":1406,"status":190,"phases":1407,"primaryCompletion":746,"start":1408,"enrollment":503,"conditions":1409,"interventions":1410},"NCT00609921","A Phase 1 Study of ARQ 197 in Patients With Solid Tumors",[85],"2008-01",[26],[1398],{"trials":1412,"activeCount":96},[],{"trials":1414,"activeCount":96},[1415],{"nctId":1416,"briefTitle":1417,"status":190,"phases":1418,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":1421,"conditions":1422,"interventions":1424},"NCT02029157","A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)",[87],"2017-08","2014-01",386,[1423],"Liver Cancer",[1398],{"trials":1426,"activeCount":96},[],{"trials":1428,"activeCount":96},[],{"intervention":1430,"totalTrials":152,"cells":1431},"EN3267",{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1436,"PHASE3":1438,"PHASE4":1455,"NA":1457},{"trials":1433,"activeCount":96},[],{"trials":1435,"activeCount":96},[],{"trials":1437,"activeCount":96},[],{"trials":1439,"activeCount":96},[1440,1448],{"nctId":1441,"briefTitle":1442,"status":190,"phases":1443,"primaryCompletion":502,"completion":1444,"start":1445,"conditions":1446,"interventions":1447},"NCT00262678","Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.",[87],"2009-01","2005-12",[32,26],[1430],{"nctId":1449,"briefTitle":1450,"status":190,"phases":1451,"primaryCompletion":502,"completion":1444,"start":1445,"enrollment":1452,"conditions":1453,"interventions":1454},"NCT00263575","Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients",[87],139,[32,26],[1430],{"trials":1456,"activeCount":96},[],{"trials":1458,"activeCount":96},[],{"intervention":1460,"totalTrials":152,"cells":1461},"darbepoetin alfa",{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1477,"PHASE4":1487,"NA":1489},{"trials":1463,"activeCount":96},[],{"trials":1465,"activeCount":96},[],{"trials":1467,"activeCount":96},[1468],{"nctId":1469,"briefTitle":1470,"status":190,"phases":1471,"primaryCompletion":1472,"start":1016,"enrollment":1473,"conditions":1474,"interventions":1476},"NCT00359840","A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor",[86],"2007-09",120,[1475],"Anemia",[1460],{"trials":1478,"activeCount":96},[1479],{"nctId":1480,"briefTitle":1481,"status":190,"phases":1482,"primaryCompletion":1483,"start":718,"enrollment":1484,"conditions":1485,"interventions":1486},"NCT00344409","A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients",[87],"2007-05",200,[1475],[1460],{"trials":1488,"activeCount":96},[],{"trials":1490,"activeCount":96},[],{"intervention":988,"totalTrials":152,"cells":1492},{"EARLY_PHASE1":1493,"PHASE1":1495,"PHASE2":1497,"PHASE3":1509,"PHASE4":1515,"NA":1517},{"trials":1494,"activeCount":96},[],{"trials":1496,"activeCount":96},[],{"trials":1498,"activeCount":96},[1499],{"nctId":1500,"briefTitle":1501,"status":190,"phases":1502,"primaryCompletion":816,"completion":816,"start":511,"enrollment":1503,"conditions":1504,"interventions":1505},"NCT02216656","Phase 2 Study of KHK7580",[86],201,[20],[1506,1507,1508,988],"KHK7580 low dose","KHK7580 middle dose","KHK7580 high dose",{"trials":1510,"activeCount":96},[1511],{"nctId":981,"briefTitle":964,"status":190,"phases":1512,"primaryCompletion":983,"completion":983,"start":984,"enrollment":985,"conditions":1513,"interventions":1514},[86,87],[20],[926,988],{"trials":1516,"activeCount":96},[],{"trials":1518,"activeCount":96},[],{"intervention":1520,"totalTrials":92,"cells":1521},"Cinacalcet HCl",{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1537,"NA":1539},{"trials":1523,"activeCount":96},[],{"trials":1525,"activeCount":96},[],{"trials":1527,"activeCount":96},[],{"trials":1529,"activeCount":96},[1530],{"nctId":1531,"briefTitle":1532,"status":190,"phases":1533,"primaryCompletion":808,"completion":808,"start":787,"conditions":1534,"interventions":1536},"NCT01460030","An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism",[87],[977,1535,978],"Hypercalcemia",[1520],{"trials":1538,"activeCount":96},[],{"trials":1540,"activeCount":96},[],{"intervention":1542,"totalTrials":92,"cells":1543},"Istradefylline 20 mg or 40 mg",{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1550,"PHASE4":1561,"NA":1563},{"trials":1545,"activeCount":96},[],{"trials":1547,"activeCount":96},[],{"trials":1549,"activeCount":96},[],{"trials":1551,"activeCount":96},[1552],{"nctId":1553,"briefTitle":1554,"status":190,"phases":1555,"primaryCompletion":1556,"completion":1556,"start":1557,"enrollment":1558,"conditions":1559,"interventions":1560},"NCT02610231","Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease",[87],"2017-12-20","2015-12",239,[1390],[1542],{"trials":1562,"activeCount":96},[],{"trials":1564,"activeCount":96},[],{"intervention":1566,"totalTrials":92,"cells":1567},"AMG 531",{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1574,"PHASE4":1584,"NA":1586},{"trials":1569,"activeCount":96},[],{"trials":1571,"activeCount":96},[],{"trials":1573,"activeCount":96},[],{"trials":1575,"activeCount":96},[1576],{"nctId":1577,"briefTitle":1578,"status":190,"phases":1579,"primaryCompletion":1224,"completion":746,"start":1116,"enrollment":1580,"conditions":1581,"interventions":1583},"NCT00440037","Open Label Extension Study of AMG 531 in Japanese Subjects With ITP",[86,87],44,[1582],"Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",[1566],{"trials":1585,"activeCount":96},[],{"trials":1587,"activeCount":96},[],{"intervention":961,"totalTrials":92,"cells":1589},{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1596,"PHASE4":1602,"NA":1604},{"trials":1591,"activeCount":96},[],{"trials":1593,"activeCount":96},[],{"trials":1595,"activeCount":96},[],{"trials":1597,"activeCount":96},[1598],{"nctId":953,"briefTitle":954,"status":190,"phases":1599,"primaryCompletion":956,"completion":956,"start":957,"enrollment":958,"conditions":1600,"interventions":1601},[87],[20],[926,961],{"trials":1603,"activeCount":96},[],{"trials":1605,"activeCount":96},[],{"intervention":1607,"totalTrials":92,"cells":1608},"OPC-262 2.5 mg",{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1615,"PHASE4":1625,"NA":1627},{"trials":1610,"activeCount":96},[],{"trials":1612,"activeCount":96},[],{"trials":1614,"activeCount":96},[],{"trials":1616,"activeCount":96},[1617],{"nctId":1618,"briefTitle":1222,"status":190,"phases":1619,"primaryCompletion":1319,"completion":1319,"start":1063,"enrollment":1620,"conditions":1621,"interventions":1623},"NCT00997282",[86,87],255,[1622],"Diabetes Type 2",[1607,1624],"OPC-262 5 mg",{"trials":1626,"activeCount":96},[],{"trials":1628,"activeCount":96},[],{"intervention":1624,"totalTrials":92,"cells":1630},{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1637,"PHASE4":1643,"NA":1645},{"trials":1632,"activeCount":96},[],{"trials":1634,"activeCount":96},[],{"trials":1636,"activeCount":96},[],{"trials":1638,"activeCount":96},[1639],{"nctId":1618,"briefTitle":1222,"status":190,"phases":1640,"primaryCompletion":1319,"completion":1319,"start":1063,"enrollment":1620,"conditions":1641,"interventions":1642},[86,87],[1622],[1607,1624],{"trials":1644,"activeCount":96},[],{"trials":1646,"activeCount":96},[],{"intervention":1189,"totalTrials":92,"cells":1648},{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1655,"PHASE4":1661,"NA":1663},{"trials":1650,"activeCount":96},[],{"trials":1652,"activeCount":96},[],{"trials":1654,"activeCount":96},[],{"trials":1656,"activeCount":96},[1657],{"nctId":1182,"briefTitle":1183,"status":190,"phases":1658,"primaryCompletion":501,"completion":501,"start":1185,"enrollment":1186,"conditions":1659,"interventions":1660},[87],[1179],[1155,1189],{"trials":1662,"activeCount":96},[],{"trials":1664,"activeCount":96},[],{"intervention":1666,"totalTrials":92,"cells":1667},"saxaglipitin",{"EARLY_PHASE1":1668,"PHASE1":1670,"PHASE2":1672,"PHASE3":1674,"PHASE4":1684,"NA":1686},{"trials":1669,"activeCount":96},[],{"trials":1671,"activeCount":96},[],{"trials":1673,"activeCount":96},[],{"trials":1675,"activeCount":96},[1676],{"nctId":1677,"briefTitle":1678,"status":190,"phases":1679,"primaryCompletion":1680,"completion":1680,"start":1233,"enrollment":699,"conditions":1681,"interventions":1683},"NCT01162876","A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus",[87],"2010-11",[1682],"Diabetes",[1666],{"trials":1685,"activeCount":96},[],{"trials":1687,"activeCount":96},[],{"intervention":1323,"totalTrials":92,"cells":1689},{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1696,"PHASE4":1702,"NA":1704},{"trials":1691,"activeCount":96},[],{"trials":1693,"activeCount":96},[],{"trials":1695,"activeCount":96},[],{"trials":1697,"activeCount":96},[1698],{"nctId":1316,"briefTitle":1317,"status":190,"phases":1699,"primaryCompletion":1319,"completion":1319,"start":1304,"enrollment":1320,"conditions":1700,"interventions":1701},[87],[15],[1289,1323],{"trials":1703,"activeCount":96},[],{"trials":1705,"activeCount":96},[],{"intervention":1707,"totalTrials":92,"cells":1708},"KHK4827 140mg SC",{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1715,"PHASE4":1727,"NA":1729},{"trials":1710,"activeCount":96},[],{"trials":1712,"activeCount":96},[],{"trials":1714,"activeCount":96},[],{"trials":1716,"activeCount":96},[1717],{"nctId":1718,"briefTitle":1719,"status":190,"phases":1720,"primaryCompletion":1721,"completion":620,"start":1722,"enrollment":1723,"conditions":1724,"interventions":1725},"NCT02052609","A Phase 3 Clinical Study of KHK 4827",[87],"2015-01-28","2014-02",155,[623,624,625,626],[1707,1726],"KHK4827 210mg SC",{"trials":1728,"activeCount":96},[],{"trials":1730,"activeCount":96},[],{"intervention":1726,"totalTrials":92,"cells":1732},{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1737,"PHASE3":1739,"PHASE4":1745,"NA":1747},{"trials":1734,"activeCount":96},[],{"trials":1736,"activeCount":96},[],{"trials":1738,"activeCount":96},[],{"trials":1740,"activeCount":96},[1741],{"nctId":1718,"briefTitle":1719,"status":190,"phases":1742,"primaryCompletion":1721,"completion":620,"start":1722,"enrollment":1723,"conditions":1743,"interventions":1744},[87],[623,624,625,626],[1707,1726],{"trials":1746,"activeCount":96},[],{"trials":1748,"activeCount":96},[],{"intervention":1750,"totalTrials":92,"cells":1751},"KW-0761 0.3 mg\u002Fkg IV",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1771,"NA":1773},{"trials":1753,"activeCount":96},[],{"trials":1755,"activeCount":96},[],{"trials":1757,"activeCount":96},[],{"trials":1759,"activeCount":96},[1760],{"nctId":1761,"briefTitle":1762,"status":124,"phases":1763,"primaryCompletion":1764,"completion":1765,"start":1766,"enrollment":1767,"conditions":1768,"interventions":1770},"NCT03191526","A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)",[87],"2019-06-06","2021-08-31","2017-05-22",66,[1769],"HTLV-1 Associated Myelopathy",[1750],{"trials":1772,"activeCount":96},[],{"trials":1774,"activeCount":96},[],{"intervention":1776,"totalTrials":92,"cells":1777},"Brodalumab",{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1784,"PHASE4":1796,"NA":1798},{"trials":1779,"activeCount":96},[],{"trials":1781,"activeCount":96},[],{"trials":1783,"activeCount":96},[],{"trials":1785,"activeCount":96},[1786],{"nctId":1787,"briefTitle":1788,"status":190,"phases":1789,"primaryCompletion":1790,"completion":1790,"start":1791,"enrollment":1792,"conditions":1793,"interventions":1795},"NCT02985983","A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)",[87],"2019-09-23","2017-03-07",159,[1794],"Axial Spondyloarthritis",[1776],{"trials":1797,"activeCount":96},[],{"trials":1799,"activeCount":96},[],{"intervention":1392,"totalTrials":92,"cells":1801},{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1806,"PHASE3":1808,"PHASE4":1814,"NA":1816},{"trials":1803,"activeCount":96},[],{"trials":1805,"activeCount":96},[],{"trials":1807,"activeCount":96},[],{"trials":1809,"activeCount":96},[1810],{"nctId":1384,"briefTitle":1385,"status":190,"phases":1811,"primaryCompletion":1387,"completion":1387,"start":531,"enrollment":1388,"conditions":1812,"interventions":1813},[87],[1390],[1366,1392],{"trials":1815,"activeCount":96},[],{"trials":1817,"activeCount":96},[],{"intervention":1819,"totalTrials":92,"cells":1820},"Antithrombin gamma",{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1827,"PHASE4":1841,"NA":1843},{"trials":1822,"activeCount":96},[],{"trials":1824,"activeCount":96},[],{"trials":1826,"activeCount":96},[],{"trials":1828,"activeCount":96},[1829],{"nctId":1830,"briefTitle":1831,"status":190,"phases":1832,"primaryCompletion":1833,"completion":1834,"start":1835,"enrollment":1836,"conditions":1837,"interventions":1839},"NCT04182373","KW-3357 Study in Patients With Early Onset Severe Preeclampsia",[87],"2023-05-17","2023-06-16","2019-11-19",181,[1838],"Preeclampsia",[1819,1840],"physiological saline",{"trials":1842,"activeCount":96},[],{"trials":1844,"activeCount":96},[],{"intervention":1840,"totalTrials":92,"cells":1846},{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1853,"PHASE4":1859,"NA":1861},{"trials":1848,"activeCount":96},[],{"trials":1850,"activeCount":96},[],{"trials":1852,"activeCount":96},[],{"trials":1854,"activeCount":96},[1855],{"nctId":1830,"briefTitle":1831,"status":190,"phases":1856,"primaryCompletion":1833,"completion":1834,"start":1835,"enrollment":1836,"conditions":1857,"interventions":1858},[87],[1838],[1819,1840],{"trials":1860,"activeCount":96},[],{"trials":1862,"activeCount":96},[],{"intervention":1864,"totalTrials":18,"cells":1865},"KW-0761",{"EARLY_PHASE1":1866,"PHASE1":1868,"PHASE2":1880,"PHASE3":1931,"PHASE4":1933,"NA":1935},{"trials":1867,"activeCount":96},[],{"trials":1869,"activeCount":96},[1870],{"nctId":1871,"briefTitle":1872,"status":190,"phases":1873,"primaryCompletion":1874,"completion":1874,"start":1875,"enrollment":554,"conditions":1876,"interventions":1879},"NCT00355472","Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL",[85],"2008-10","2007-02",[1877,1878],"Adult T-Cell Leukemia and Lymphoma (ATL)","Adult Peripheral T-Cell Lymphoma (PTCL)",[1864],{"trials":1881,"activeCount":96},[1882,1891,1901,1909,1917,1925],{"nctId":1883,"briefTitle":1884,"status":190,"phases":1885,"primaryCompletion":786,"completion":786,"start":1886,"enrollment":92,"conditions":1887,"interventions":1890},"NCT01226472","Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001",[86],"2010-08",[1888,1889],"Peripheral T-cell Lymphoma","Cutaneous T-cell Lymphoma",[1864],{"nctId":1892,"briefTitle":1893,"status":190,"phases":1894,"primaryCompletion":1895,"completion":1895,"start":1896,"enrollment":1897,"conditions":1898,"interventions":1900},"NCT01192984","Study of KW-0761 in Subjects With CCR4-positive Peripheral T\u002FNK-cell Lymphoma",[86],"2012-05","2010-09",38,[1899],"Peripheral T\u002FNK-cell Lymphoma",[1864],{"nctId":1902,"briefTitle":1903,"status":190,"phases":1904,"primaryCompletion":1905,"completion":1905,"start":1232,"enrollment":1897,"conditions":1906,"interventions":1908},"NCT01611142","Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)",[86],"2015-05",[1907],"Peripheral T-Cell Lymphoma",[1864],{"nctId":1910,"briefTitle":1911,"status":190,"phases":1912,"primaryCompletion":1232,"completion":1232,"start":1233,"enrollment":1580,"conditions":1913,"interventions":1915},"NCT01173887","Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15",[86],[1914],"Adult T-cell Leukemia-Lymphoma",[1916,1864],"VCAP\u002FAMP\u002FVECP",{"nctId":1918,"briefTitle":1919,"status":190,"phases":1920,"primaryCompletion":1233,"completion":1680,"start":1921,"enrollment":586,"conditions":1922,"interventions":1924},"NCT00920790","Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma",[86],"2009-06",[1923],"Adult T-cell Leukemia-lymphoma",[1864],{"nctId":1926,"briefTitle":1927,"status":190,"phases":1928,"primaryCompletion":786,"completion":786,"start":1072,"enrollment":503,"conditions":1929,"interventions":1930},"NCT00888927","Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma",[85,86],[1907],[1864],{"trials":1932,"activeCount":96},[],{"trials":1934,"activeCount":96},[],{"trials":1936,"activeCount":96},[],{"intervention":1938,"totalTrials":24,"cells":1939},"KW-6356",{"EARLY_PHASE1":1940,"PHASE1":1942,"PHASE2":1975,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1941,"activeCount":96},[],{"trials":1943,"activeCount":96},[1944,1956,1965],{"nctId":1945,"briefTitle":1946,"status":190,"phases":1947,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":1950,"conditions":1951,"interventions":1952},"NCT03970798","A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin",[85],"2019-07-31","2019-05-22",50,[15],[1953,1954,1955,1938],"Midazolam","Caffeine","Rosuvastatin",{"nctId":1957,"briefTitle":1958,"status":190,"phases":1959,"primaryCompletion":1835,"completion":1835,"start":1960,"enrollment":699,"conditions":1961,"interventions":1962},"NCT04070495","A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin",[85],"2019-08-27",[15],[1938,1963,1964],"Clarithromycin","Rifampicin",{"nctId":1966,"briefTitle":1967,"status":190,"phases":1968,"primaryCompletion":1969,"completion":1969,"start":1970,"enrollment":1971,"conditions":1972,"interventions":1973},"NCT04342273","A Through QT\u002FQTc Study of KW-6356",[85],"2020-09-05","2020-03-31",128,[15],[1938,1938,1974],"Moxifloxacin",{"trials":1976,"activeCount":96},[1977,1986],{"nctId":1978,"briefTitle":1979,"status":190,"phases":1980,"primaryCompletion":1981,"completion":1981,"start":1982,"enrollment":1983,"conditions":1984,"interventions":1985},"NCT03703570","A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations",[86],"2020-04-15","2018-09-29",502,[15],[1938],{"nctId":1987,"briefTitle":1988,"status":190,"phases":1989,"primaryCompletion":1990,"completion":1991,"start":1992,"enrollment":1993,"conditions":1994,"interventions":1995},"NCT02939391","A Study of KW-6356 in Subjects With Early Parkinson's Disease",[86],"2017-11-22","2017-12-08","2016-09",175,[15],[1938,1938],{"trials":1997,"activeCount":96},[],{"trials":1999,"activeCount":96},[],{"trials":2001,"activeCount":96},[],{"intervention":2003,"totalTrials":33,"cells":2004},"ARQ 197",{"EARLY_PHASE1":2005,"PHASE1":2007,"PHASE2":2017,"PHASE3":2034,"PHASE4":2036,"NA":2038},{"trials":2006,"activeCount":96},[],{"trials":2008,"activeCount":96},[2009],{"nctId":2010,"briefTitle":2011,"status":190,"phases":2012,"primaryCompletion":945,"completion":945,"start":2013,"enrollment":225,"conditions":2014,"interventions":2016},"NCT01656265","Study of ARQ 197 in Hepatocellular Carcinoma (HCC)",[85],"2012-07",[2015],"Advanced Hepatocellular Carcinoma",[2003],{"trials":2018,"activeCount":96},[2019,2027],{"nctId":2020,"briefTitle":2021,"status":190,"phases":2022,"primaryCompletion":1303,"completion":1303,"start":2023,"enrollment":1320,"conditions":2024,"interventions":2026},"NCT01152645","Study of ARQ 197 Monotherapy",[86],"2010-06",[2025],"Gastric Cancer",[2003],{"nctId":2028,"briefTitle":2029,"status":190,"phases":2030,"primaryCompletion":2031,"completion":2031,"start":1895,"enrollment":1017,"conditions":2032,"interventions":2033},"NCT01580735","ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer",[86],"2015-04",[1348],[2003],{"trials":2035,"activeCount":96},[],{"trials":2037,"activeCount":96},[],{"trials":2039,"activeCount":96},[],{"intervention":2041,"totalTrials":33,"cells":2042},"RTA 402",{"EARLY_PHASE1":2043,"PHASE1":2045,"PHASE2":2047,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2044,"activeCount":96},[],{"trials":2046,"activeCount":96},[],{"trials":2048,"activeCount":96},[2049,2058,2065],{"nctId":2050,"briefTitle":2051,"status":124,"phases":2052,"primaryCompletion":2053,"completion":2053,"start":542,"enrollment":2054,"conditions":2055,"interventions":2057},"NCT01572610","A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus",[86],"2013-11",11,[2056,28],"Chronic Kidney Disease",[2041],{"nctId":2059,"briefTitle":2060,"status":124,"phases":2061,"primaryCompletion":2053,"completion":2053,"start":542,"enrollment":2062,"conditions":2063,"interventions":2064},"NCT01574365","A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus",[86],53,[2056,28],[2041],{"nctId":2066,"briefTitle":2067,"status":190,"phases":2068,"primaryCompletion":1146,"completion":2069,"start":697,"enrollment":2070,"conditions":2071,"interventions":2072},"NCT02316821","The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study",[86],"2017-09",216,[2056,28],[2041],{"trials":2074,"activeCount":96},[],{"trials":2076,"activeCount":96},[],{"trials":2078,"activeCount":96},[],{"intervention":2080,"totalTrials":152,"cells":2081},"Exemestane",{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2094,"PHASE3":2107,"PHASE4":2109,"NA":2111},{"trials":2083,"activeCount":96},[],{"trials":2085,"activeCount":96},[2086],{"nctId":2087,"briefTitle":2088,"status":190,"phases":2089,"primaryCompletion":522,"completion":522,"start":1358,"enrollment":483,"conditions":2090,"interventions":2092},"NCT02623751","Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer",[85],[2091],"Breast Cancer",[2093,2080],"KHK2375",{"trials":2095,"activeCount":96},[2096],{"nctId":2097,"briefTitle":2098,"status":190,"phases":2099,"primaryCompletion":1264,"completion":2100,"start":2101,"enrollment":2102,"conditions":2103,"interventions":2105},"NCT03291886","Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer",[86],"2021-03-26","2017-09-22",133,[2104],"Advanced or Recurrent Breast Cancer",[2106,2106,2080],"Entinostat",{"trials":2108,"activeCount":96},[],{"trials":2110,"activeCount":96},[],{"trials":2112,"activeCount":96},[],{"intervention":2114,"totalTrials":152,"cells":2115},"pegfilgrastim",{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2142,"PHASE4":2144,"NA":2146},{"trials":2117,"activeCount":96},[],{"trials":2119,"activeCount":96},[],{"trials":2121,"activeCount":96},[2122,2130],{"nctId":2123,"briefTitle":2124,"status":190,"phases":2125,"primaryCompletion":1027,"completion":1027,"start":718,"enrollment":2126,"conditions":2127,"interventions":2129},"NCT00364468","Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients",[86],107,[2128],"Neutropenia",[2114],{"nctId":2131,"briefTitle":2132,"status":190,"phases":2133,"primaryCompletion":2134,"completion":2135,"start":2136,"enrollment":2137,"conditions":2138,"interventions":2140},"NCT03993639","KRN125 for Mobilization of Hematopoietic Stem Cells",[86],"2020-07-21","2020-08-28","2019-05-28",35,[2139],"Peripheral Blood Stem Cell Transplantation",[2141],"Pegfilgrastim",{"trials":2143,"activeCount":96},[],{"trials":2145,"activeCount":96},[],{"trials":2147,"activeCount":96},[],{"intervention":2149,"totalTrials":152,"cells":2150},"KW-2478",{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2166,"PHASE3":2177,"PHASE4":2179,"NA":2181},{"trials":2152,"activeCount":96},[],{"trials":2154,"activeCount":96},[2155],{"nctId":2156,"briefTitle":2157,"status":190,"phases":2158,"primaryCompletion":1886,"completion":2159,"start":2160,"enrollment":563,"conditions":2161,"interventions":2165},"NCT00457782","A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma",[85],"2011-01","2007-04",[2162,2163,2164],"Multiple Myeloma","Chronic Lymphocytic Leukaemia","B-cell Non-Hodgkin's Lymphoma",[2149],{"trials":2167,"activeCount":96},[2168],{"nctId":2169,"briefTitle":2170,"status":190,"phases":2171,"primaryCompletion":2053,"completion":2053,"start":2172,"enrollment":2173,"conditions":2174,"interventions":2175},"NCT01063907","A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and\u002For Refractory Multiple Myeloma",[85,86],"2010-03",95,[2162],[2149,2176],"Bortezomib",{"trials":2178,"activeCount":96},[],{"trials":2180,"activeCount":96},[],{"trials":2182,"activeCount":96},[],{"intervention":2184,"totalTrials":92,"cells":2185},"apomorphine hydrochloride",{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2190,"PHASE3":2199,"PHASE4":2201,"NA":2203},{"trials":2187,"activeCount":96},[],{"trials":2189,"activeCount":96},[],{"trials":2191,"activeCount":96},[2192],{"nctId":2193,"briefTitle":2194,"status":190,"phases":2195,"primaryCompletion":1874,"completion":1874,"start":2196,"enrollment":554,"conditions":2197,"interventions":2198},"NCT00610103","Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy",[86],"2007-11",[15],[2184],{"trials":2200,"activeCount":96},[],{"trials":2202,"activeCount":96},[],{"trials":2204,"activeCount":96},[],{"intervention":2106,"totalTrials":92,"cells":2206},{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2217,"PHASE4":2219,"NA":2221},{"trials":2208,"activeCount":96},[],{"trials":2210,"activeCount":96},[],{"trials":2212,"activeCount":96},[2213],{"nctId":2097,"briefTitle":2098,"status":190,"phases":2214,"primaryCompletion":1264,"completion":2100,"start":2101,"enrollment":2102,"conditions":2215,"interventions":2216},[86],[2104],[2106,2106,2080],{"trials":2218,"activeCount":96},[],{"trials":2220,"activeCount":96},[],{"trials":2222,"activeCount":96},[],{"intervention":2224,"totalTrials":92,"cells":2225},"KHK6188",{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2240,"PHASE4":2242,"NA":2244},{"trials":2227,"activeCount":96},[],{"trials":2229,"activeCount":96},[],{"trials":2231,"activeCount":96},[2232],{"nctId":2233,"briefTitle":2234,"status":190,"phases":2235,"primaryCompletion":2236,"completion":2236,"start":542,"enrollment":503,"conditions":2237,"interventions":2239},"NCT01544296","A Comparative Study of KHK6188",[86],"2013-06",[2238],"Postherpetic Neuralgia",[2224],{"trials":2241,"activeCount":96},[],{"trials":2243,"activeCount":96},[],{"trials":2245,"activeCount":96},[],{"intervention":2247,"totalTrials":92,"cells":2248},"KRN321",{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2253,"PHASE3":2263,"PHASE4":2265,"NA":2267},{"trials":2250,"activeCount":96},[],{"trials":2252,"activeCount":96},[],{"trials":2254,"activeCount":96},[2255],{"nctId":2256,"briefTitle":2257,"status":190,"phases":2258,"primaryCompletion":1722,"completion":1722,"start":500,"enrollment":2259,"conditions":2260,"interventions":2262},"NCT01497145","A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome",[86],45,[2261],"MDS",[2247],{"trials":2264,"activeCount":96},[],{"trials":2266,"activeCount":96},[],{"trials":2268,"activeCount":96},[],{"intervention":2270,"totalTrials":92,"cells":2271},"KRN125",{"EARLY_PHASE1":2272,"PHASE1":2274,"PHASE2":2276,"PHASE3":2288,"PHASE4":2290,"NA":2292},{"trials":2273,"activeCount":96},[],{"trials":2275,"activeCount":96},[],{"trials":2277,"activeCount":96},[2278],{"nctId":2279,"briefTitle":2280,"status":190,"phases":2281,"primaryCompletion":2282,"completion":2282,"start":2283,"enrollment":729,"conditions":2284,"interventions":2286},"NCT05007652","A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma",[86],"2022-10-25","2021-09-01",[2285],"Multiple Myeloma and Malignant Lymphoma",[2270,2287],"KRN8601",{"trials":2289,"activeCount":96},[],{"trials":2291,"activeCount":96},[],{"trials":2293,"activeCount":96},[],{"intervention":2287,"totalTrials":92,"cells":2295},{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2300,"PHASE3":2306,"PHASE4":2308,"NA":2310},{"trials":2297,"activeCount":96},[],{"trials":2299,"activeCount":96},[],{"trials":2301,"activeCount":96},[2302],{"nctId":2279,"briefTitle":2280,"status":190,"phases":2303,"primaryCompletion":2282,"completion":2282,"start":2283,"enrollment":729,"conditions":2304,"interventions":2305},[86],[2285],[2270,2287],{"trials":2307,"activeCount":96},[],{"trials":2309,"activeCount":96},[],{"trials":2311,"activeCount":96},[],{"intervention":1916,"totalTrials":92,"cells":2313},{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2324,"PHASE4":2326,"NA":2328},{"trials":2315,"activeCount":96},[],{"trials":2317,"activeCount":96},[],{"trials":2319,"activeCount":96},[2320],{"nctId":1910,"briefTitle":1911,"status":190,"phases":2321,"primaryCompletion":1232,"completion":1232,"start":1233,"enrollment":1580,"conditions":2322,"interventions":2323},[86],[1914],[1916,1864],{"trials":2325,"activeCount":96},[],{"trials":2327,"activeCount":96},[],{"trials":2329,"activeCount":96},[],{"intervention":2176,"totalTrials":92,"cells":2331},{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2342,"PHASE4":2344,"NA":2346},{"trials":2333,"activeCount":96},[],{"trials":2335,"activeCount":96},[],{"trials":2337,"activeCount":96},[2338],{"nctId":2169,"briefTitle":2170,"status":190,"phases":2339,"primaryCompletion":2053,"completion":2053,"start":2172,"enrollment":2173,"conditions":2340,"interventions":2341},[85,86],[2162],[2149,2176],{"trials":2343,"activeCount":96},[],{"trials":2345,"activeCount":96},[],{"trials":2347,"activeCount":96},[],{"intervention":2349,"totalTrials":92,"cells":2350},"saxagliptin",{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2365,"PHASE4":2367,"NA":2369},{"trials":2352,"activeCount":96},[],{"trials":2354,"activeCount":96},[],{"trials":2356,"activeCount":96},[2357],{"nctId":2358,"briefTitle":2359,"status":190,"phases":2360,"primaryCompletion":2172,"completion":2361,"start":1444,"enrollment":2362,"conditions":2363,"interventions":2364},"NCT00857558","A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes",[86],"2010-05",350,[1218],[2349,2349,2349],{"trials":2366,"activeCount":96},[],{"trials":2368,"activeCount":96},[],{"trials":2370,"activeCount":96},[],{"intervention":2372,"totalTrials":92,"cells":2373},"KHK4577",{"EARLY_PHASE1":2374,"PHASE1":2376,"PHASE2":2378,"PHASE3":2388,"PHASE4":2390,"NA":2392},{"trials":2375,"activeCount":96},[],{"trials":2377,"activeCount":96},[],{"trials":2379,"activeCount":96},[2380],{"nctId":2381,"briefTitle":2382,"status":190,"phases":2383,"primaryCompletion":697,"completion":697,"start":2053,"enrollment":2384,"conditions":2385,"interventions":2387},"NCT02004119","Phase 2 Study of KHK4577",[86],93,[2386],"Atopic Dermatitis",[2372],{"trials":2389,"activeCount":96},[],{"trials":2391,"activeCount":96},[],{"trials":2393,"activeCount":96},[],{"intervention":1506,"totalTrials":92,"cells":2395},{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2400,"PHASE3":2406,"PHASE4":2408,"NA":2410},{"trials":2397,"activeCount":96},[],{"trials":2399,"activeCount":96},[],{"trials":2401,"activeCount":96},[2402],{"nctId":1500,"briefTitle":1501,"status":190,"phases":2403,"primaryCompletion":816,"completion":816,"start":511,"enrollment":1503,"conditions":2404,"interventions":2405},[86],[20],[1506,1507,1508,988],{"trials":2407,"activeCount":96},[],{"trials":2409,"activeCount":96},[],{"trials":2411,"activeCount":96},[],{"intervention":1507,"totalTrials":92,"cells":2413},{"EARLY_PHASE1":2414,"PHASE1":2416,"PHASE2":2418,"PHASE3":2424,"PHASE4":2426,"NA":2428},{"trials":2415,"activeCount":96},[],{"trials":2417,"activeCount":96},[],{"trials":2419,"activeCount":96},[2420],{"nctId":1500,"briefTitle":1501,"status":190,"phases":2421,"primaryCompletion":816,"completion":816,"start":511,"enrollment":1503,"conditions":2422,"interventions":2423},[86],[20],[1506,1507,1508,988],{"trials":2425,"activeCount":96},[],{"trials":2427,"activeCount":96},[],{"trials":2429,"activeCount":96},[],{"intervention":1508,"totalTrials":92,"cells":2431},{"EARLY_PHASE1":2432,"PHASE1":2434,"PHASE2":2436,"PHASE3":2442,"PHASE4":2444,"NA":2446},{"trials":2433,"activeCount":96},[],{"trials":2435,"activeCount":96},[],{"trials":2437,"activeCount":96},[2438],{"nctId":1500,"briefTitle":1501,"status":190,"phases":2439,"primaryCompletion":816,"completion":816,"start":511,"enrollment":1503,"conditions":2440,"interventions":2441},[86],[20],[1506,1507,1508,988],{"trials":2443,"activeCount":96},[],{"trials":2445,"activeCount":96},[],{"trials":2447,"activeCount":96},[],{"intervention":2449,"totalTrials":92,"cells":2450},"KHK4563",{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2466,"PHASE4":2468,"NA":2470},{"trials":2452,"activeCount":96},[],{"trials":2454,"activeCount":96},[],{"trials":2456,"activeCount":96},[2457],{"nctId":2458,"briefTitle":2459,"status":190,"phases":2460,"primaryCompletion":2461,"completion":531,"start":1303,"enrollment":2462,"conditions":2463,"interventions":2465},"NCT01412736","A Phase IIa Study of KHK4563",[86],"2013-07",106,[2464],"Uncontrolled and Suspected Eosinophilic Asthma",[2449,2449,2449],{"trials":2467,"activeCount":96},[],{"trials":2469,"activeCount":96},[],{"trials":2471,"activeCount":96},[],{"intervention":2473,"totalTrials":92,"cells":2474},"KRN330",{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2491,"PHASE4":2493,"NA":2495},{"trials":2476,"activeCount":96},[],{"trials":2478,"activeCount":96},[],{"trials":2480,"activeCount":96},[2481],{"nctId":2482,"briefTitle":2483,"status":124,"phases":2484,"primaryCompletion":2013,"completion":1177,"start":2485,"enrollment":2486,"conditions":2487,"interventions":2489},"NCT00838578","Phase I\u002FII Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer",[85,86],"2009-03",65,[2488],"Colorectal Cancer",[2473,2490],"Irinotecan",{"trials":2492,"activeCount":96},[],{"trials":2494,"activeCount":96},[],{"trials":2496,"activeCount":96},[],{"intervention":2490,"totalTrials":92,"cells":2498},{"EARLY_PHASE1":2499,"PHASE1":2501,"PHASE2":2503,"PHASE3":2509,"PHASE4":2511,"NA":2513},{"trials":2500,"activeCount":96},[],{"trials":2502,"activeCount":96},[],{"trials":2504,"activeCount":96},[2505],{"nctId":2482,"briefTitle":2483,"status":124,"phases":2506,"primaryCompletion":2013,"completion":1177,"start":2485,"enrollment":2486,"conditions":2507,"interventions":2508},[85,86],[2488],[2473,2490],{"trials":2510,"activeCount":96},[],{"trials":2512,"activeCount":96},[],{"trials":2514,"activeCount":96},[],{"intervention":2516,"totalTrials":92,"cells":2517},"benralizumab",{"EARLY_PHASE1":2518,"PHASE1":2520,"PHASE2":2522,"PHASE3":2534,"PHASE4":2536,"NA":2538},{"trials":2519,"activeCount":96},[],{"trials":2521,"activeCount":96},[],{"trials":2523,"activeCount":96},[2524],{"nctId":2525,"briefTitle":2526,"status":190,"phases":2527,"primaryCompletion":2528,"completion":2528,"start":2529,"enrollment":2530,"conditions":2531,"interventions":2533},"NCT02772419","Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis",[86],"2017-03-27","2016-06",63,[2532],"Eosinophilic Chronic Rhinosinusitis",[2516,2516],{"trials":2535,"activeCount":96},[],{"trials":2537,"activeCount":96},[],{"trials":2539,"activeCount":96},[],{"intervention":883,"totalTrials":92,"cells":2541},{"EARLY_PHASE1":2542,"PHASE1":2544,"PHASE2":2546,"PHASE3":2552,"PHASE4":2554,"NA":2556},{"trials":2543,"activeCount":96},[],{"trials":2545,"activeCount":96},[],{"trials":2547,"activeCount":96},[2548],{"nctId":876,"briefTitle":877,"status":190,"phases":2549,"primaryCompletion":879,"completion":879,"start":193,"enrollment":880,"conditions":2550,"interventions":2551},[86],[17],[848,883],{"trials":2553,"activeCount":96},[],{"trials":2555,"activeCount":96},[],{"trials":2557,"activeCount":96},[],{"intervention":2559,"totalTrials":33,"cells":2560},"KHK6640",{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2591,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2562,"activeCount":96},[],{"trials":2564,"activeCount":96},[2565,2574,2584],{"nctId":2566,"briefTitle":2567,"status":190,"phases":2568,"primaryCompletion":2569,"completion":2569,"start":511,"enrollment":2570,"conditions":2571,"interventions":2573},"NCT02127476","A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease",[85],"2017-05",57,[2572],"Alzheimer's Disease",[2559],{"nctId":2575,"briefTitle":2576,"status":190,"phases":2577,"primaryCompletion":2578,"completion":2578,"start":2579,"enrollment":2580,"conditions":2581,"interventions":2583},"NCT03093519","A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease",[85],"2017-12-06","2017-03-03",21,[2582],"Alzheimer Disease",[2559],{"nctId":2585,"briefTitle":2586,"status":190,"phases":2587,"primaryCompletion":1992,"completion":1992,"start":2588,"enrollment":699,"conditions":2589,"interventions":2590},"NCT02377713","A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.",[85],"2015-03",[2572],[2559],{"trials":2592,"activeCount":96},[],{"trials":2594,"activeCount":96},[],{"trials":2596,"activeCount":96},[],{"trials":2598,"activeCount":96},[],{"intervention":2600,"totalTrials":152,"cells":2601},"KHK4083",{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2625,"PHASE3":2627,"PHASE4":2629,"NA":2631},{"trials":2603,"activeCount":96},[],{"trials":2605,"activeCount":96},[2606,2616],{"nctId":2607,"briefTitle":2608,"status":190,"phases":2609,"primaryCompletion":2610,"completion":2610,"start":2611,"enrollment":2612,"conditions":2613,"interventions":2615},"NCT03096223","A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis",[85],"2018-02-07","2017-04-10",26,[2614],"Dermatitis, Atopic",[2600],{"nctId":2617,"briefTitle":2618,"status":190,"phases":2619,"primaryCompletion":2620,"completion":2620,"start":2621,"enrollment":1723,"conditions":2622,"interventions":2624},"NCT02985593","A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis",[85],"2017-12-26","2016-12",[2623],"Healthy Men and Subjects With Ulcerative Colitis",[2600],{"trials":2626,"activeCount":96},[],{"trials":2628,"activeCount":96},[],{"trials":2630,"activeCount":96},[],{"trials":2632,"activeCount":96},[],{"intervention":1953,"totalTrials":92,"cells":2634},{"EARLY_PHASE1":2635,"PHASE1":2637,"PHASE2":2643,"PHASE3":2645,"PHASE4":2647,"NA":2649},{"trials":2636,"activeCount":96},[],{"trials":2638,"activeCount":96},[2639],{"nctId":1945,"briefTitle":1946,"status":190,"phases":2640,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":1950,"conditions":2641,"interventions":2642},[85],[15],[1953,1954,1955,1938],{"trials":2644,"activeCount":96},[],{"trials":2646,"activeCount":96},[],{"trials":2648,"activeCount":96},[],{"trials":2650,"activeCount":96},[],{"intervention":1954,"totalTrials":92,"cells":2652},{"EARLY_PHASE1":2653,"PHASE1":2655,"PHASE2":2661,"PHASE3":2663,"PHASE4":2665,"NA":2667},{"trials":2654,"activeCount":96},[],{"trials":2656,"activeCount":96},[2657],{"nctId":1945,"briefTitle":1946,"status":190,"phases":2658,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":1950,"conditions":2659,"interventions":2660},[85],[15],[1953,1954,1955,1938],{"trials":2662,"activeCount":96},[],{"trials":2664,"activeCount":96},[],{"trials":2666,"activeCount":96},[],{"trials":2668,"activeCount":96},[],{"intervention":1955,"totalTrials":92,"cells":2670},{"EARLY_PHASE1":2671,"PHASE1":2673,"PHASE2":2679,"PHASE3":2681,"PHASE4":2683,"NA":2685},{"trials":2672,"activeCount":96},[],{"trials":2674,"activeCount":96},[2675],{"nctId":1945,"briefTitle":1946,"status":190,"phases":2676,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":1950,"conditions":2677,"interventions":2678},[85],[15],[1953,1954,1955,1938],{"trials":2680,"activeCount":96},[],{"trials":2682,"activeCount":96},[],{"trials":2684,"activeCount":96},[],{"trials":2686,"activeCount":96},[],{"intervention":1378,"totalTrials":92,"cells":2688},{"EARLY_PHASE1":2689,"PHASE1":2691,"PHASE2":2697,"PHASE3":2699,"PHASE4":2701,"NA":2703},{"trials":2690,"activeCount":96},[],{"trials":2692,"activeCount":96},[2693],{"nctId":1373,"briefTitle":1374,"status":190,"phases":2694,"primaryCompletion":698,"completion":697,"start":541,"enrollment":699,"conditions":2695,"interventions":2696},[85],[15],[1366,1378],{"trials":2698,"activeCount":96},[],{"trials":2700,"activeCount":96},[],{"trials":2702,"activeCount":96},[],{"trials":2704,"activeCount":96},[],{"intervention":1963,"totalTrials":92,"cells":2706},{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2715,"PHASE3":2717,"PHASE4":2719,"NA":2721},{"trials":2708,"activeCount":96},[],{"trials":2710,"activeCount":96},[2711],{"nctId":1957,"briefTitle":1958,"status":190,"phases":2712,"primaryCompletion":1835,"completion":1835,"start":1960,"enrollment":699,"conditions":2713,"interventions":2714},[85],[15],[1938,1963,1964],{"trials":2716,"activeCount":96},[],{"trials":2718,"activeCount":96},[],{"trials":2720,"activeCount":96},[],{"trials":2722,"activeCount":96},[],{"intervention":1964,"totalTrials":92,"cells":2724},{"EARLY_PHASE1":2725,"PHASE1":2727,"PHASE2":2733,"PHASE3":2735,"PHASE4":2737,"NA":2739},{"trials":2726,"activeCount":96},[],{"trials":2728,"activeCount":96},[2729],{"nctId":1957,"briefTitle":1958,"status":190,"phases":2730,"primaryCompletion":1835,"completion":1835,"start":1960,"enrollment":699,"conditions":2731,"interventions":2732},[85],[15],[1938,1963,1964],{"trials":2734,"activeCount":96},[],{"trials":2736,"activeCount":96},[],{"trials":2738,"activeCount":96},[],{"trials":2740,"activeCount":96},[],{"intervention":2742,"totalTrials":92,"cells":2743},"KHK2898",{"EARLY_PHASE1":2744,"PHASE1":2746,"PHASE2":2756,"PHASE3":2758,"PHASE4":2760,"NA":2762},{"trials":2745,"activeCount":96},[],{"trials":2747,"activeCount":96},[2748],{"nctId":2749,"briefTitle":2750,"status":124,"phases":2751,"primaryCompletion":1905,"completion":1905,"start":2752,"enrollment":194,"conditions":2753,"interventions":2755},"NCT01516645","Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors",[85],"2012-01",[2754],"Solid Tumour",[2742],{"trials":2757,"activeCount":96},[],{"trials":2759,"activeCount":96},[],{"trials":2761,"activeCount":96},[],{"trials":2763,"activeCount":96},[],{"intervention":2765,"totalTrials":92,"cells":2766},"KW-2450",{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2778,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2768,"activeCount":96},[],{"trials":2770,"activeCount":96},[2771],{"nctId":2772,"briefTitle":2773,"status":190,"phases":2774,"primaryCompletion":1886,"completion":1886,"start":1921,"enrollment":8,"conditions":2775,"interventions":2777},"NCT00921336","Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor",[85],[2776],"Solid Tumor",[2765],{"trials":2779,"activeCount":96},[],{"trials":2781,"activeCount":96},[],{"trials":2783,"activeCount":96},[],{"trials":2785,"activeCount":96},[],{"intervention":2787,"totalTrials":92,"cells":2788},"LY2523355",{"EARLY_PHASE1":2789,"PHASE1":2791,"PHASE2":2802,"PHASE3":2804,"PHASE4":2806,"NA":2808},{"trials":2790,"activeCount":96},[],{"trials":2792,"activeCount":96},[2793],{"nctId":2794,"briefTitle":2795,"status":190,"phases":2796,"primaryCompletion":2797,"completion":2797,"start":2798,"enrollment":596,"conditions":2799,"interventions":2801},"NCT01358019","A Study of LY2523355 in Patients With Solid Cancer",[85],"2013-01","2011-05",[2800],"Solid Tumors",[2787],{"trials":2803,"activeCount":96},[],{"trials":2805,"activeCount":96},[],{"trials":2807,"activeCount":96},[],{"trials":2809,"activeCount":96},[],{"intervention":2811,"totalTrials":92,"cells":2812},"1mg KHK7580",{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2830,"PHASE3":2832,"PHASE4":2834,"NA":2836},{"trials":2814,"activeCount":96},[],{"trials":2816,"activeCount":96},[2817],{"nctId":2818,"briefTitle":2819,"status":190,"phases":2820,"primaryCompletion":2821,"completion":2821,"start":2822,"enrollment":503,"conditions":2823,"interventions":2825},"NCT04206657","Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers",[85],"2021-06-17","2019-12-20",[2824],"Healthy Volunteer",[2811,2826,2827,2828,2829],"3mg KHK7580","6mg KHK7580","12mg KHK7580","6mg KHK7580 for 8days",{"trials":2831,"activeCount":96},[],{"trials":2833,"activeCount":96},[],{"trials":2835,"activeCount":96},[],{"trials":2837,"activeCount":96},[],{"intervention":2826,"totalTrials":92,"cells":2839},{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2848,"PHASE3":2850,"PHASE4":2852,"NA":2854},{"trials":2841,"activeCount":96},[],{"trials":2843,"activeCount":96},[2844],{"nctId":2818,"briefTitle":2819,"status":190,"phases":2845,"primaryCompletion":2821,"completion":2821,"start":2822,"enrollment":503,"conditions":2846,"interventions":2847},[85],[2824],[2811,2826,2827,2828,2829],{"trials":2849,"activeCount":96},[],{"trials":2851,"activeCount":96},[],{"trials":2853,"activeCount":96},[],{"trials":2855,"activeCount":96},[],{"intervention":2827,"totalTrials":92,"cells":2857},{"EARLY_PHASE1":2858,"PHASE1":2860,"PHASE2":2866,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2859,"activeCount":96},[],{"trials":2861,"activeCount":96},[2862],{"nctId":2818,"briefTitle":2819,"status":190,"phases":2863,"primaryCompletion":2821,"completion":2821,"start":2822,"enrollment":503,"conditions":2864,"interventions":2865},[85],[2824],[2811,2826,2827,2828,2829],{"trials":2867,"activeCount":96},[],{"trials":2869,"activeCount":96},[],{"trials":2871,"activeCount":96},[],{"trials":2873,"activeCount":96},[],{"intervention":2828,"totalTrials":92,"cells":2875},{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2884,"PHASE3":2886,"PHASE4":2888,"NA":2890},{"trials":2877,"activeCount":96},[],{"trials":2879,"activeCount":96},[2880],{"nctId":2818,"briefTitle":2819,"status":190,"phases":2881,"primaryCompletion":2821,"completion":2821,"start":2822,"enrollment":503,"conditions":2882,"interventions":2883},[85],[2824],[2811,2826,2827,2828,2829],{"trials":2885,"activeCount":96},[],{"trials":2887,"activeCount":96},[],{"trials":2889,"activeCount":96},[],{"trials":2891,"activeCount":96},[],{"intervention":2829,"totalTrials":92,"cells":2893},{"EARLY_PHASE1":2894,"PHASE1":2896,"PHASE2":2902,"PHASE3":2904,"PHASE4":2906,"NA":2908},{"trials":2895,"activeCount":96},[],{"trials":2897,"activeCount":96},[2898],{"nctId":2818,"briefTitle":2819,"status":190,"phases":2899,"primaryCompletion":2821,"completion":2821,"start":2822,"enrollment":503,"conditions":2900,"interventions":2901},[85],[2824],[2811,2826,2827,2828,2829],{"trials":2903,"activeCount":96},[],{"trials":2905,"activeCount":96},[],{"trials":2907,"activeCount":96},[],{"trials":2909,"activeCount":96},[],{"intervention":2911,"totalTrials":92,"cells":2912},"KW-2449",{"EARLY_PHASE1":2913,"PHASE1":2915,"PHASE2":2925,"PHASE3":2927,"PHASE4":2929,"NA":2931},{"trials":2914,"activeCount":96},[],{"trials":2916,"activeCount":96},[2917],{"nctId":2918,"briefTitle":2919,"status":124,"phases":2920,"primaryCompletion":2921,"completion":1311,"start":1444,"enrollment":194,"conditions":2922,"interventions":2924},"NCT00779480","Safety, Tolerability, and Pharmacokinetic\u002FPharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)",[85],"2010-04",[2923],"Acute Myelogenous Leukemia (AML)",[2911],{"trials":2926,"activeCount":96},[],{"trials":2928,"activeCount":96},[],{"trials":2930,"activeCount":96},[],{"trials":2932,"activeCount":96},[],{"intervention":692,"totalTrials":92,"cells":2934},{"EARLY_PHASE1":2935,"PHASE1":2937,"PHASE2":2943,"PHASE3":2945,"PHASE4":2947,"NA":2949},{"trials":2936,"activeCount":96},[],{"trials":2938,"activeCount":96},[2939],{"nctId":684,"briefTitle":685,"status":190,"phases":2940,"primaryCompletion":687,"completion":687,"start":688,"enrollment":503,"conditions":2941,"interventions":2942},[85],[690],[676,692],{"trials":2944,"activeCount":96},[],{"trials":2946,"activeCount":96},[],{"trials":2948,"activeCount":96},[],{"trials":2950,"activeCount":96},[],{"intervention":2952,"totalTrials":92,"cells":2953},"KHK2866",{"EARLY_PHASE1":2954,"PHASE1":2956,"PHASE2":2971,"PHASE3":2973,"PHASE4":2975,"NA":2977},{"trials":2955,"activeCount":96},[],{"trials":2957,"activeCount":96},[2958],{"nctId":2959,"briefTitle":2960,"status":124,"phases":2961,"primaryCompletion":1339,"completion":1339,"start":2159,"enrollment":1255,"conditions":2962,"interventions":2967},"NCT01279291","Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer",[85],[2963,2964,2965,2966],"Neoplasms","Ovarian Neoplasms","Fallopian Tube Neoplasms","Primary Peritoneal Neoplasm",[2952,2968,2969,2970],"Gemcitabine and Carboplatin","paclitaxel","pegylated liposomal doxorubicin",{"trials":2972,"activeCount":96},[],{"trials":2974,"activeCount":96},[],{"trials":2976,"activeCount":96},[],{"trials":2978,"activeCount":96},[],{"intervention":2968,"totalTrials":92,"cells":2980},{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2989,"PHASE3":2991,"PHASE4":2993,"NA":2995},{"trials":2982,"activeCount":96},[],{"trials":2984,"activeCount":96},[2985],{"nctId":2959,"briefTitle":2960,"status":124,"phases":2986,"primaryCompletion":1339,"completion":1339,"start":2159,"enrollment":1255,"conditions":2987,"interventions":2988},[85],[2963,2964,2965,2966],[2952,2968,2969,2970],{"trials":2990,"activeCount":96},[],{"trials":2992,"activeCount":96},[],{"trials":2994,"activeCount":96},[],{"trials":2996,"activeCount":96},[],{"intervention":2969,"totalTrials":92,"cells":2998},{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3007,"PHASE3":3009,"PHASE4":3011,"NA":3013},{"trials":3000,"activeCount":96},[],{"trials":3002,"activeCount":96},[3003],{"nctId":2959,"briefTitle":2960,"status":124,"phases":3004,"primaryCompletion":1339,"completion":1339,"start":2159,"enrollment":1255,"conditions":3005,"interventions":3006},[85],[2963,2964,2965,2966],[2952,2968,2969,2970],{"trials":3008,"activeCount":96},[],{"trials":3010,"activeCount":96},[],{"trials":3012,"activeCount":96},[],{"trials":3014,"activeCount":96},[],{"intervention":2970,"totalTrials":92,"cells":3016},{"EARLY_PHASE1":3017,"PHASE1":3019,"PHASE2":3025,"PHASE3":3027,"PHASE4":3029,"NA":3031},{"trials":3018,"activeCount":96},[],{"trials":3020,"activeCount":96},[3021],{"nctId":2959,"briefTitle":2960,"status":124,"phases":3022,"primaryCompletion":1339,"completion":1339,"start":2159,"enrollment":1255,"conditions":3023,"interventions":3024},[85],[2963,2964,2965,2966],[2952,2968,2969,2970],{"trials":3026,"activeCount":96},[],{"trials":3028,"activeCount":96},[],{"trials":3030,"activeCount":96},[],{"trials":3032,"activeCount":96},[],{"intervention":3034,"totalTrials":92,"cells":3035},"KW-6356 Low Dose",{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3052,"PHASE3":3054,"PHASE4":3056,"NA":3058},{"trials":3037,"activeCount":96},[],{"trials":3039,"activeCount":96},[3040],{"nctId":3041,"briefTitle":3042,"status":190,"phases":3043,"primaryCompletion":3044,"completion":3044,"start":3045,"enrollment":788,"conditions":3046,"interventions":3047},"NCT03830528","A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects",[85],"2019-10-10","2019-02-26",[15],[3034,3048,3049,3050,3051],"KW-6356 Middle Dose","KW-6356 High Dose","KW-6356 X Dose","KW-6356 Y Dose",{"trials":3053,"activeCount":96},[],{"trials":3055,"activeCount":96},[],{"trials":3057,"activeCount":96},[],{"trials":3059,"activeCount":96},[],{"intervention":3048,"totalTrials":92,"cells":3061},{"EARLY_PHASE1":3062,"PHASE1":3064,"PHASE2":3070,"PHASE3":3072,"PHASE4":3074,"NA":3076},{"trials":3063,"activeCount":96},[],{"trials":3065,"activeCount":96},[3066],{"nctId":3041,"briefTitle":3042,"status":190,"phases":3067,"primaryCompletion":3044,"completion":3044,"start":3045,"enrollment":788,"conditions":3068,"interventions":3069},[85],[15],[3034,3048,3049,3050,3051],{"trials":3071,"activeCount":96},[],{"trials":3073,"activeCount":96},[],{"trials":3075,"activeCount":96},[],{"trials":3077,"activeCount":96},[],{"intervention":3049,"totalTrials":92,"cells":3079},{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3088,"PHASE3":3090,"PHASE4":3092,"NA":3094},{"trials":3081,"activeCount":96},[],{"trials":3083,"activeCount":96},[3084],{"nctId":3041,"briefTitle":3042,"status":190,"phases":3085,"primaryCompletion":3044,"completion":3044,"start":3045,"enrollment":788,"conditions":3086,"interventions":3087},[85],[15],[3034,3048,3049,3050,3051],{"trials":3089,"activeCount":96},[],{"trials":3091,"activeCount":96},[],{"trials":3093,"activeCount":96},[],{"trials":3095,"activeCount":96},[],{"intervention":3050,"totalTrials":92,"cells":3097},{"EARLY_PHASE1":3098,"PHASE1":3100,"PHASE2":3106,"PHASE3":3108,"PHASE4":3110,"NA":3112},{"trials":3099,"activeCount":96},[],{"trials":3101,"activeCount":96},[3102],{"nctId":3041,"briefTitle":3042,"status":190,"phases":3103,"primaryCompletion":3044,"completion":3044,"start":3045,"enrollment":788,"conditions":3104,"interventions":3105},[85],[15],[3034,3048,3049,3050,3051],{"trials":3107,"activeCount":96},[],{"trials":3109,"activeCount":96},[],{"trials":3111,"activeCount":96},[],{"trials":3113,"activeCount":96},[],{"intervention":3051,"totalTrials":92,"cells":3115},{"EARLY_PHASE1":3116,"PHASE1":3118,"PHASE2":3124,"PHASE3":3126,"PHASE4":3128,"NA":3130},{"trials":3117,"activeCount":96},[],{"trials":3119,"activeCount":96},[3120],{"nctId":3041,"briefTitle":3042,"status":190,"phases":3121,"primaryCompletion":3044,"completion":3044,"start":3045,"enrollment":788,"conditions":3122,"interventions":3123},[85],[15],[3034,3048,3049,3050,3051],{"trials":3125,"activeCount":96},[],{"trials":3127,"activeCount":96},[],{"trials":3129,"activeCount":96},[],{"trials":3131,"activeCount":96},[],{"intervention":2093,"totalTrials":92,"cells":3133},{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3142,"PHASE3":3144,"PHASE4":3146,"NA":3148},{"trials":3135,"activeCount":96},[],{"trials":3137,"activeCount":96},[3138],{"nctId":2087,"briefTitle":2088,"status":190,"phases":3139,"primaryCompletion":522,"completion":522,"start":1358,"enrollment":483,"conditions":3140,"interventions":3141},[85],[2091],[2093,2080],{"trials":3143,"activeCount":96},[],{"trials":3145,"activeCount":96},[],{"trials":3147,"activeCount":96},[],{"trials":3149,"activeCount":96},[],{"intervention":1974,"totalTrials":92,"cells":3151},{"EARLY_PHASE1":3152,"PHASE1":3154,"PHASE2":3160,"PHASE3":3162,"PHASE4":3164,"NA":3166},{"trials":3153,"activeCount":96},[],{"trials":3155,"activeCount":96},[3156],{"nctId":1966,"briefTitle":1967,"status":190,"phases":3157,"primaryCompletion":1969,"completion":1969,"start":1970,"enrollment":1971,"conditions":3158,"interventions":3159},[85],[15],[1938,1938,1974],{"trials":3161,"activeCount":96},[],{"trials":3163,"activeCount":96},[],{"trials":3165,"activeCount":96},[],{"trials":3167,"activeCount":96},[],{"intervention":3169,"totalTrials":92,"cells":3170},"granisetron IV",{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3182,"PHASE3":3184,"PHASE4":3186,"NA":3188},{"trials":3172,"activeCount":96},[],{"trials":3174,"activeCount":96},[3175],{"nctId":3176,"briefTitle":3177,"status":190,"phases":3178,"primaryCompletion":2921,"completion":2921,"start":2172,"enrollment":554,"conditions":3179,"interventions":3180},"NCT01073696","Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy Subjects",[85],[1075],[3169,3181],"granisetron patch",{"trials":3183,"activeCount":96},[],{"trials":3185,"activeCount":96},[],{"trials":3187,"activeCount":96},[],{"trials":3189,"activeCount":96},[],{"intervention":3181,"totalTrials":92,"cells":3191},{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3200,"PHASE3":3202,"PHASE4":3204,"NA":3206},{"trials":3193,"activeCount":96},[],{"trials":3195,"activeCount":96},[3196],{"nctId":3176,"briefTitle":3177,"status":190,"phases":3197,"primaryCompletion":2921,"completion":2921,"start":2172,"enrollment":554,"conditions":3198,"interventions":3199},[85],[1075],[3169,3181],{"trials":3201,"activeCount":96},[],{"trials":3203,"activeCount":96},[],{"trials":3205,"activeCount":96},[],{"trials":3207,"activeCount":96},[],{"intervention":3209,"totalTrials":92,"cells":3210},"Mogamulizumab: KW-0761, Nivolumab:",{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3223,"PHASE3":3225,"PHASE4":3227,"NA":3229},{"trials":3212,"activeCount":96},[],{"trials":3214,"activeCount":96},[3215],{"nctId":3216,"briefTitle":3217,"status":190,"phases":3218,"primaryCompletion":2610,"completion":3219,"start":510,"enrollment":3220,"conditions":3221,"interventions":3222},"NCT02476123","Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538\u002FBMS-936558) in Subjects With Advanced Solid Tumors",[85],"2018-12-21",118,[2776],[3209],{"trials":3224,"activeCount":96},[],{"trials":3226,"activeCount":96},[],{"trials":3228,"activeCount":96},[],{"trials":3230,"activeCount":96},[],{"intervention":3232,"totalTrials":92,"cells":3233},"CEP-37250\u002FKHK2804",{"EARLY_PHASE1":3234,"PHASE1":3236,"PHASE2":3248,"PHASE3":3250,"PHASE4":3252,"NA":3254},{"trials":3235,"activeCount":96},[],{"trials":3237,"activeCount":96},[3238],{"nctId":3239,"briefTitle":3240,"status":190,"phases":3241,"primaryCompletion":3242,"completion":3242,"start":1026,"enrollment":3243,"conditions":3244,"interventions":3247},"NCT01447732","Phase 1 Study of CEP-37250\u002FKHK2804 in Subjects With Advanced Solid Tumors",[85],"2015-01",71,[2754,3245,3246],"Adenocarcinoma of the Colorectal","Adenocarcinoma of the Pancreas",[3232],{"trials":3249,"activeCount":96},[],{"trials":3251,"activeCount":96},[],{"trials":3253,"activeCount":96},[],{"trials":3255,"activeCount":96},[],{"intervention":3257,"totalTrials":92,"cells":3258},"KHK4323 IV\u002FS",{"EARLY_PHASE1":3259,"PHASE1":3261,"PHASE2":3273,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3260,"activeCount":96},[],{"trials":3262,"activeCount":96},[3263],{"nctId":3264,"briefTitle":3265,"status":124,"phases":3266,"primaryCompletion":3267,"completion":3267,"start":3268,"enrollment":24,"conditions":3269,"interventions":3270},"NCT03846466","Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis",[85],"2019-12-11","2019-02-22",[2386],[3257,3271,3272],"KHK4323 SC\u002FS","KHK4323 IV\u002FM",{"trials":3274,"activeCount":96},[],{"trials":3276,"activeCount":96},[],{"trials":3278,"activeCount":96},[],{"trials":3280,"activeCount":96},[],{"intervention":3271,"totalTrials":92,"cells":3282},{"EARLY_PHASE1":3283,"PHASE1":3285,"PHASE2":3291,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3284,"activeCount":96},[],{"trials":3286,"activeCount":96},[3287],{"nctId":3264,"briefTitle":3265,"status":124,"phases":3288,"primaryCompletion":3267,"completion":3267,"start":3268,"enrollment":24,"conditions":3289,"interventions":3290},[85],[2386],[3257,3271,3272],{"trials":3292,"activeCount":96},[],{"trials":3294,"activeCount":96},[],{"trials":3296,"activeCount":96},[],{"trials":3298,"activeCount":96},[],{"intervention":3272,"totalTrials":92,"cells":3300},{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3309,"PHASE3":3311,"PHASE4":3313,"NA":3315},{"trials":3302,"activeCount":96},[],{"trials":3304,"activeCount":96},[3305],{"nctId":3264,"briefTitle":3265,"status":124,"phases":3306,"primaryCompletion":3267,"completion":3267,"start":3268,"enrollment":24,"conditions":3307,"interventions":3308},[85],[2386],[3257,3271,3272],{"trials":3310,"activeCount":96},[],{"trials":3312,"activeCount":96},[],{"trials":3314,"activeCount":96},[],{"trials":3316,"activeCount":96},[],{"intervention":3318,"totalTrials":92,"cells":3319},"KW-2450 in combination with lapatinib and letrozole",{"EARLY_PHASE1":3320,"PHASE1":3322,"PHASE2":3330,"PHASE3":3332,"PHASE4":3334,"NA":3336},{"trials":3321,"activeCount":96},[],{"trials":3323,"activeCount":96},[3324],{"nctId":3325,"briefTitle":3326,"status":124,"phases":3327,"primaryCompletion":798,"completion":798,"start":1311,"enrollment":2054,"conditions":3328,"interventions":3329},"NCT01199367","Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer",[85],[2091],[3318],{"trials":3331,"activeCount":96},[],{"trials":3333,"activeCount":96},[],{"trials":3335,"activeCount":96},[],{"trials":3337,"activeCount":96},[],{"intervention":3339,"totalTrials":92,"cells":3340},"BIW-8962",{"EARLY_PHASE1":3341,"PHASE1":3343,"PHASE2":3351,"PHASE3":3353,"PHASE4":3355,"NA":3357},{"trials":3342,"activeCount":96},[],{"trials":3344,"activeCount":96},[3345],{"nctId":3346,"briefTitle":3347,"status":124,"phases":3348,"primaryCompletion":2798,"completion":1026,"start":1874,"enrollment":543,"conditions":3349,"interventions":3350},"NCT00775502","Phase 1\u002F2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma",[85],[2162],[3339],{"trials":3352,"activeCount":96},[],{"trials":3354,"activeCount":96},[],{"trials":3356,"activeCount":96},[],{"trials":3358,"activeCount":96},[],{"intervention":3360,"totalTrials":92,"cells":3361},"KRN951",{"EARLY_PHASE1":3362,"PHASE1":3364,"PHASE2":3372,"PHASE3":3374,"PHASE4":3376,"NA":3378},{"trials":3363,"activeCount":96},[],{"trials":3365,"activeCount":96},[3366],{"nctId":3367,"briefTitle":3368,"status":190,"phases":3369,"primaryCompletion":523,"completion":523,"start":1081,"enrollment":1073,"conditions":3370,"interventions":3371},"NCT00970411","Study of KRN951 in Patients With Solid Tumors",[85],[2800],[3360],{"trials":3373,"activeCount":96},[],{"trials":3375,"activeCount":96},[],{"trials":3377,"activeCount":96},[],{"trials":3379,"activeCount":96},[],{"intervention":3381,"totalTrials":92,"cells":3382},"Burosumab",{"EARLY_PHASE1":3383,"PHASE1":3385,"PHASE2":3387,"PHASE3":3389,"PHASE4":3391,"NA":3393},{"trials":3384,"activeCount":96},[],{"trials":3386,"activeCount":96},[],{"trials":3388,"activeCount":96},[],{"trials":3390,"activeCount":96},[],{"trials":3392,"activeCount":96},[],{"trials":3394,"activeCount":96},[3395],{"nctId":3396,"briefTitle":3397,"status":3398,"phases":3399,"conditions":3400,"interventions":3402},"NCT03775187","Expanded Access to Burosumab","AVAILABLE",[],[23,3401],"Tumor-Induced Osteomalacia",[3381]]